{
  "doc_id": "18",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "盘点降糖药物的中国指南/共识(下)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "盘点降糖药物的中国指南/共识(下)",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [],
          "relations": [],
          "sentence_en": "Review of China's guidelines/consensus on hypoglycemic drugs (Part 2)"
        }
      ],
      "paragraph_en": "Review of China's guidelines/consensus on hypoglycemic drugs (Part 2)"
    },
    {
      "paragraph_id": "1",
      "paragraph": "近几年，国外新药进入中国市场的速度似乎逐渐加快，这些新药无疑给血糖管理增添了新的选择，基于国内外的研究证据，国内学术组织已经发布了一些针对这些新药的指南或共识，这有助于规范用临床应用，下面就让我们一起去了解这些新型降糖药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "近几年，国外新药进入中国市场的速度似乎逐渐加快，这些新药无疑给血糖管理增添了新的选择，基于国内外的研究证据，国内学术组织已经发布了一些针对这些新药的指南或共识，这有助于规范用临床应用，下面就让我们一起去了解这些新型降糖药。",
          "start_idx": 0,
          "end_idx": 111,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "In recent years, the speed at which new foreign drugs enter the Chinese market seems to be gradually accelerating. These new drugs have undoubtedly added new options for blood sugar management. Based on research evidence at home and abroad, domestic academic organizations have issued some guidelines or consensus for these new drugs, which will help standardize their clinical applications. Let us now learn about these new glucose-lowering drugs together."
        }
      ],
      "paragraph_en": "In recent years, the speed at which new foreign drugs enter the Chinese market seems to be gradually accelerating. These new drugs have undoubtedly added new options for blood sugar management. Based on research evidence at home and abroad, domestic academic organizations have issued some guidelines or consensus for these new drugs, which will help standardize their clinical applications. Let us now learn about these new glucose-lowering drugs together."
    },
    {
      "paragraph_id": "2",
      "paragraph": "现在，我国临床上可供选择的降糖药物已达到九种，其中二肽基肽酶IV(DPP- 4)抑制剂、胰高血糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是最近几年刚刚进入我国，但由于作用机制不同于传统的降糖药物，迅速成为热门药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "现在，我国临床上可供选择的降糖药物已达到九种，其中二肽基肽酶IV(DPP- 4)抑制剂、胰高血糖素样肽1(GLP-1)受体激动剂和钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂是最近几年刚刚进入我国，但由于作用机制不同于传统的降糖药物，迅速成为热门药物。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "二肽基肽酶IV(DPP- 4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 43,
              "entity_en": "Dipeptidyl peptidase IV (DPP-4) inhibitors"
            },
            {
              "entity_id": "T2",
              "entity": "胰高血糖素样肽1(GLP-1)受体激动剂",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 64,
              "entity_en": "Glucagon-like peptide 1 (GLP-1) receptor agonists"
            },
            {
              "entity_id": "T3",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 87,
              "entity_en": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "At present, there are nine kinds of glucose-lowering drugs available for clinical use in my country. Among them, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT-2) inhibitors have just entered my country in recent years, but because their mechanisms of action are different from traditional glucose-lowering drugs, they have quickly become popular drugs."
        }
      ],
      "paragraph_en": "At present, there are nine kinds of glucose-lowering drugs available for clinical use in my country. Among them, dipeptidyl peptidase IV (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT-2) inhibitors have just entered my country in recent years, but because their mechanisms of action are different from traditional glucose-lowering drugs, they have quickly become popular drugs."
    },
    {
      "paragraph_id": "3",
      "paragraph": "DPP-4抑制剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP-4抑制剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [
            {
              "entity_id": "T4",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "DPP-4 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "DPP-4 inhibitors: (Consensus on the clinical application of glucose-lowering drugs based on glucagon-like peptide 1/Rapid advice guidelines for the clinical application of incretin-based drug therapy)"
        }
      ],
      "paragraph_en": "DPP-4 inhibitors: (Consensus on the clinical application of glucose-lowering drugs based on glucagon-like peptide 1/Rapid advice guidelines for the clinical application of incretin-based drug therapy)"
    },
    {
      "paragraph_id": "4",
      "paragraph": "胃肠道是机体重要的内分泌器官，其分泌的肠促胰素所引起的胰岛素分泌约占全部胰岛素分泌量的50%~70%，而且肠促胰素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。正因为如此，人们研发出了模拟肠促胰素的GLP-1受体激动剂和延缓肠促胰素降解的DPP- 4抑制剂。目前国内已经上市了两种GLP-1受体激动剂(艾塞那肽和利拉鲁肽)和5种DPP-4抑制剂(西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀)(见表1)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "胃肠道是机体重要的内分泌器官，其分泌的肠促胰素所引起的胰岛素分泌约占全部胰岛素分泌量的50%~70%，而且肠促胰素刺激胰岛素分泌的作用具有葡萄糖浓度依赖的特点，故在调节血糖的同时，引起低血糖的风险很低。",
          "start_idx": 0,
          "end_idx": 101,
          "entities": [
            {
              "entity_id": "T5",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 95,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T6",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 84,
              "end_idx": 86,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R0",
              "head_entity_id": "T6",
              "tail_entity_id": "T5"
            }
          ],
          "sentence_en": "The gastrointestinal tract is an important endocrine organ of the body. The insulin secretion caused by the incretins secreted by it accounts for about 50% to 70% of the total insulin secretion. Moreover, the effect of incretins in stimulating insulin secretion is dependent on glucose concentration. Therefore, while regulating blood sugar, the risk of causing hypoglycemia is very low."
        },
        {
          "sentence_id": "1",
          "sentence": "正因为如此，人们研发出了模拟肠促胰素的GLP-1受体激动剂和延缓肠促胰素降解的DPP- 4抑制剂。",
          "start_idx": 101,
          "end_idx": 150,
          "entities": [
            {
              "entity_id": "T7",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 29,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T8",
              "entity": "DPP- 4抑制剂",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 48,
              "entity_en": "DPP-4 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "For this reason, GLP-1 receptor agonists that mimic incretin and DPP-4 inhibitors that delay incretin degradation have been developed."
        },
        {
          "sentence_id": "2",
          "sentence": "目前国内已经上市了两种GLP-1受体激动剂(艾塞那肽和利拉鲁肽)和5种DPP-4抑制剂(西格列汀、维格列汀、沙格列汀、利格列汀和阿格列汀)(见表1)。",
          "start_idx": 150,
          "end_idx": 225,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 21,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T10",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T11",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 31,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T12",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 43,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T13",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T14",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T15",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T16",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T17",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 68,
              "entity_en": "Alogliptin"
            }
          ],
          "relations": [],
          "sentence_en": "Currently, two GLP-1 receptor agonists (exenatide and liraglutide) and five DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) have been launched in China (see Table 1)."
        }
      ],
      "paragraph_en": "The gastrointestinal tract is an important endocrine organ of the body. The insulin secretion caused by the incretin secretion accounts for about 50% to 70% of the total insulin secretion. In addition, the effect of incretin on insulin secretion is dependent on glucose concentration. Therefore, while regulating blood sugar, the risk of causing hypoglycemia is very low. For this reason, people have developed GLP-1 receptor agonists that mimic incretin and DPP-4 inhibitors that delay incretin degradation. At present, two GLP-1 receptor agonists (exenatide and liraglutide) and five DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) have been launched in China (see Table 1)."
    },
    {
      "paragraph_id": "5",
      "paragraph": "中华医学会糖尿病学分会(CDS)在2014年发布了《基于胰高血糖素样肽1降糖药物的临床应用共识》(简称“临床应用共识”)；中华医学会内分泌学分会与中国药学会医院药学专业委员会在2015年年底联合发布了《基于肠促胰素的药物治疗临床应用的快速建议指南》(简称“快速建议指南”)，该指南计划于2018年进行更新，届时可能会根据新的中国证据做出一些调整。DPP-4抑制剂在2017年才被纳入医保乙类药物(即需要部分自费)，所以临床上更多地是在大城市的大医院使用，或是在其他降糖药物效果不佳时才被使用，所以在我国的糖尿病指南中的治疗地位要比快速建议指南中的地位略低一些。以下内容我们将仅仅客观分析现有证据，具体到临床应用，大家还是需要和医生共同商定。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中华医学会糖尿病学分会(CDS)在2014年发布了《基于胰高血糖素样肽1降糖药物的临床应用共识》(简称“临床应用共识”)；中华医学会内分泌学分会与中国药学会医院药学专业委员会在2015年年底联合发布了《基于肠促胰素的药物治疗临床应用的快速建议指南》(简称“快速建议指南”)，该指南计划于2018年进行更新，届时可能会根据新的中国证据做出一些调整。",
          "start_idx": 0,
          "end_idx": 173,
          "entities": [
            {
              "entity_id": "T18",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "In 2014, the Chinese Diabetes Society (CDS) issued the \"Consensus on the Clinical Application of Glucagon-like Peptide 1-based Antidiabetic Drugs\" (referred to as the \"Clinical Application Consensus\"); the Chinese Medical Association Endocrinology Society and the Hospital Pharmacy Committee of the Chinese Pharmaceutical Association jointly issued the \"Rapid Recommendation Guidelines for the Clinical Application of Incretin-based Drug Therapy\" (referred to as the \"Rapid Recommendation Guidelines\") at the end of 2015. The guidelines are scheduled to be updated in 2018, and some adjustments may be made based on new Chinese evidence."
        },
        {
          "sentence_id": "1",
          "sentence": "DPP-4抑制剂在2017年才被纳入医保乙类药物(即需要部分自费)，所以临床上更多地是在大城市的大医院使用，或是在其他降糖药物效果不佳时才被使用，所以在我国的糖尿病指南中的治疗地位要比快速建议指南中的地位略低一些。",
          "start_idx": 173,
          "end_idx": 280,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T20",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 82,
              "entity_en": "diabetes"
            }
          ],
          "relations": [],
          "sentence_en": "DPP-4 inhibitors were only included in the Class B medical insurance drugs in 2017 (i.e. they need to be partially paid for by the patient), so they are more often used clinically in large hospitals in big cities, or when other hypoglycemic drugs are ineffective. Therefore, their treatment status in my country's diabetes guidelines is slightly lower than that in the rapid advice guidelines."
        },
        {
          "sentence_id": "2",
          "sentence": "以下内容我们将仅仅客观分析现有证据，具体到临床应用，大家还是需要和医生共同商定。",
          "start_idx": 280,
          "end_idx": 320,
          "entities": [],
          "relations": [],
          "sentence_en": "In the following content, we will only objectively analyze the existing evidence. When it comes to clinical application, you still need to discuss it with your doctor."
        }
      ],
      "paragraph_en": "In 2014, the Chinese Diabetes Society (CDS) issued the \"Consensus on the Clinical Application of Glucagon-like Peptide 1-based Hypoglycemic Drugs\" (referred to as the \"Consensus on Clinical Application\"); the Chinese Medical Association Endocrinology Society and the Hospital Pharmacy Committee of the Chinese Pharmaceutical Association jointly issued the \"Rapid Recommendation Guidelines for the Clinical Application of Incretin-based Drug Therapy\" (referred to as the \"Rapid Recommendation Guidelines\") at the end of 2015. The guidelines are scheduled to be updated in 2018, and some adjustments may be made based on new Chinese evidence. DPP-4 inhibitors were only included in the Class B medical insurance drugs (i.e., they require partial self-payment) in 2017, so they are more often used in large hospitals in large cities, or when other hypoglycemic drugs are ineffective. Therefore, their treatment status in my country's diabetes guidelines is slightly lower than that in the rapid recommendation guidelines. In the following content, we will only objectively analyze the existing evidence. When it comes to clinical application, you still need to discuss with your doctor."
    },
    {
      "paragraph_id": "6",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Target Group"
        }
      ],
      "paragraph_en": "Target Group"
    },
    {
      "paragraph_id": "7",
      "paragraph": "临床应用共识指出，DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制。临床应用共识还强调，DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识指出，DPP-4抑制剂适用于成人2型糖尿病患者的血糖控制。",
          "start_idx": 0,
          "end_idx": 35,
          "entities": [
            {
              "entity_id": "T21",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 17,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T35",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T36",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T37",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T21",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T36",
              "tail_entity_id": "T35"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R3",
              "head_entity_id": "T37",
              "tail_entity_id": "T35"
            }
          ],
          "sentence_en": "The consensus on clinical application points out that DPP-4 inhibitors are suitable for blood sugar control in adults with type 2 diabetes."
        },
        {
          "sentence_id": "1",
          "sentence": "目前国内批准该类药物的适应证为：西格列汀可配合饮食控制与运动，进行单药或与二甲双胍联合使用治疗改善血糖控制；沙格列汀和阿格列汀可在饮食和运动基础上单药治疗，亦可在单独使用二甲双胍血糖控制不佳时与二甲双胍联合使用；维格列汀在二甲双胍作为单药治疗用至最大耐受剂量仍不能有效控制血糖时，与二甲双胍联合使用；利格列汀可配合饮食控制和运动，与二甲双胍和磺脲类药物联合使用改善血糖控制。",
          "start_idx": 35,
          "end_idx": 222,
          "entities": [
            {
              "entity_id": "T22",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T23",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T24",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T25",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T26",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 89,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T27",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T28",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T29",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 115,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T30",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 145,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T31",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 150,
              "end_idx": 154,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T32",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 170,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T33",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 171,
              "end_idx": 176,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T38",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 51,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T39",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 89,
              "end_idx": 91,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T40",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 136,
              "end_idx": 138,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T41",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 182,
              "end_idx": 184,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T42",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Diet control"
            },
            {
              "entity_id": "T43",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "sports"
            },
            {
              "entity_id": "T44",
              "entity": "饮食",
              "entity_type": "Treatment",
              "start_idx": 65,
              "end_idx": 67,
              "entity_en": "diet"
            },
            {
              "entity_id": "T45",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "sports"
            },
            {
              "entity_id": "T46",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 157,
              "end_idx": 161,
              "entity_en": "Diet control"
            },
            {
              "entity_id": "T47",
              "entity": "运动",
              "entity_type": "Treatment",
              "start_idx": 162,
              "end_idx": 164,
              "entity_en": "sports"
            },
            {
              "entity_id": "T48",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 91,
              "end_idx": 95,
              "entity_en": "Poor control"
            }
          ],
          "relations": [],
          "sentence_en": "Currently, the indications for this type of drug approved in China are as follows: sitagliptin can be used alone or in combination with metformin in combination with diet control and exercise to improve blood sugar control; saxagliptin and alogliptin can be used as monotherapy on the basis of diet and exercise, or in combination with metformin when blood sugar control is not good with metformin alone; vildagliptin can be used in combination with metformin when the maximum tolerated dose of metformin as a monotherapy still cannot effectively control blood sugar; linagliptin can be used in combination with metformin and sulfonylureas in combination with diet control and exercise to improve blood sugar control."
        },
        {
          "sentence_id": "2",
          "sentence": "临床应用共识还强调，DPP-4抑制剂不能用于1型糖尿病或糖尿病酮症酸中毒的患者；不推荐用于妊娠期、哺乳期妇女以及儿童。",
          "start_idx": 222,
          "end_idx": 281,
          "entities": [
            {
              "entity_id": "T34",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 18,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T49",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T50",
              "entity": "糖尿病酮症酸中毒",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 36,
              "entity_en": "Diabetic ketoacidosis"
            },
            {
              "entity_id": "T51",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "Type 1"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R4",
              "head_entity_id": "T51",
              "tail_entity_id": "T49"
            }
          ],
          "sentence_en": "The clinical application consensus also emphasizes that DPP-4 inhibitors cannot be used in patients with type 1 diabetes or diabetic ketoacidosis; they are not recommended for pregnant, lactating women and children."
        }
      ],
      "paragraph_en": "The consensus on clinical application points out that DPP-4 inhibitors are suitable for blood sugar control in adult patients with type 2 diabetes. At present, the indications of this type of drug approved in China are: sitagliptin can be used alone or in combination with metformin to improve blood sugar control in combination with diet control and exercise; saxagliptin and alogliptin can be used as monotherapy on the basis of diet and exercise, or in combination with metformin when blood sugar control is poor with metformin alone; vildagliptin is used in combination with metformin when metformin as monotherapy still cannot effectively control blood sugar at the maximum tolerated dose; linagliptin can be used in combination with metformin and sulfonylurea drugs in combination with diet control and exercise to improve blood sugar control. The consensus on clinical application also emphasizes that DPP-4 inhibitors cannot be used in patients with type 1 diabetes or diabetic ketoacidosis; they are not recommended for pregnant, lactating women and children."
    },
    {
      "paragraph_id": "8",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Clinical Usage"
        }
      ],
      "paragraph_en": "Clinical Usage"
    },
    {
      "paragraph_id": "9",
      "paragraph": "(1)起始用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)起始用药",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(1) Initial medication"
        }
      ],
      "paragraph_en": "(1) Initial medication"
    },
    {
      "paragraph_id": "10",
      "paragraph": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的一线治疗选择之一，认为在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4抑制剂可以作为一线的替代治疗药物。在刚刚结束的2017年CDS年会上，贾伟平教授简单介绍了即将发布的《中国2型糖尿病防治指南(2017年版)》(简称2017版指南)的一些内容，在高血糖治疗流程上一个主要变化是把原来的一线、二线、三线药物改为单药、二联和三联治疗，这相当于进一步强调了二甲双胍的重要地位，因为二联和三联治疗均推荐在二甲双胍基础上加用其他药物，而且在单药治疗中，二甲双胍不耐受或存在禁忌时的备选药物给出的是α一糖苷酶抑制剂和胰岛素促泌剂。个人认为，推荐α一糖苷酶抑制剂是考虑到餐后高血糖(尤其是单纯餐后高血糖)在国内很常见，推荐胰岛素促泌剂则是因为其降糖效力和二甲双胍相当，而未推荐DPP-4抑制剂一方面可能是从经济和可获得性角度考虑，另一方面可能是其降糖效力略弱。碰巧在2017年CDS年会上，纪立农教授题为《血糖达标的策略：2型糖尿病起始治疗》的报告中，恰巧也分析了起始单药治疗时，二甲双胍与DPP-4抑制剂的对比情况。2016—2017年发表的比较二甲双胍和西格列汀、阿格列汀、利格列汀的三项中国研究均发现，无论是低剂量还是高剂量(1700或2000毫克/天)的二甲双胍治疗，其降糖疗效都要优于DPP-4抑制剂。因此，纪教授的观点是，对于单药治疗患者，高剂量二甲双胍应作为常规起始治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的一线治疗选择之一，认为在二甲双胍不耐受或存在使用禁忌等情况下，DPP-4抑制剂可以作为一线的替代治疗药物。在刚刚结束的2017年CDS年会上，贾伟平教授简单介绍了即将发布的《中国2型糖尿病防治指南(2017年版)》(简称2017版指南)的一些内容，在高血糖治疗流程上一个主要变化是把原来的一线、二线、三线药物改为单药、二联和三联治疗，这相当于进一步强调了二甲双胍的重要地位，因为二联和三联治疗均推荐在二甲双胍基础上加用其他药物，而且在单药治疗中，二甲双胍不耐受或存在禁忌时的备选药物给出的是α一糖苷酶抑制剂和胰岛素促泌剂。个人认为，推荐α一糖苷酶抑制剂是考虑到餐后高血糖(尤其是单纯餐后高血糖)在国内很常见，推荐胰岛素促泌剂则是因为其降糖效力和二甲双胍相当，而未推荐DPP-4抑制剂一方面可能是从经济和可获得性角度考虑，另一方面可能是其降糖效力略弱。碰巧在2017年CDS年会上，纪立农教授题为《血糖达标的策略：2型糖尿病起始治疗》的报告中，恰巧也分析了起始单药治疗时，二甲双胍与DPP-4抑制剂的对比情况。2016—2017年发表的比较二甲双胍和西格列汀、阿格列汀、利格列汀的三项中国研究均发现，无论是低剂量还是高剂量(1700或2000毫克/天)的二甲双胍治疗，其降糖疗效都要优于DPP-4抑制剂。",
          "start_idx": 0,
          "end_idx": 577,
          "entities": [
            {
              "entity_id": "T52",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T53",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T54",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 65,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T55",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T56",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 230,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T57",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 249,
              "end_idx": 253,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T58",
              "entity": "α一糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 271,
              "end_idx": 279,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T59",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 280,
              "end_idx": 286,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T60",
              "entity": "α一糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 294,
              "end_idx": 302,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T61",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 332,
              "end_idx": 338,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T62",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 348,
              "end_idx": 352,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T63",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 359,
              "end_idx": 367,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T64",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 461,
              "end_idx": 465,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T65",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 466,
              "end_idx": 474,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T66",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 495,
              "end_idx": 499,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T67",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 500,
              "end_idx": 504,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T68",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 505,
              "end_idx": 509,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T69",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 510,
              "end_idx": 514,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T70",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 552,
              "end_idx": 556,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T71",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 568,
              "end_idx": 576,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T73",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T74",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 120,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T75",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 432,
              "end_idx": 437,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T76",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T77",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T78",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 432,
              "end_idx": 434,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T79",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 151,
              "end_idx": 154,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T80",
              "entity": "餐后高血糖",
              "entity_type": "Disease",
              "start_idx": 306,
              "end_idx": 311,
              "entity_en": "Postprandial hyperglycemia"
            },
            {
              "entity_id": "T81",
              "entity": "餐后高血糖",
              "entity_type": "Disease",
              "start_idx": 317,
              "end_idx": 322,
              "entity_en": "Postprandial hyperglycemia"
            },
            {
              "entity_id": "T82",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 424,
              "end_idx": 426,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T83",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 426,
              "end_idx": 428,
              "entity_en": "Meet the Standard"
            },
            {
              "entity_id": "T84",
              "entity": "1700或2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 537,
              "end_idx": 550,
              "entity_en": "1700 or 2000 mg/day"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R5",
              "head_entity_id": "T52",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T64",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T65",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R8",
              "head_entity_id": "T84",
              "tail_entity_id": "T70"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R9",
              "head_entity_id": "T76",
              "tail_entity_id": "T73"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R10",
              "head_entity_id": "T77",
              "tail_entity_id": "T74"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R11",
              "head_entity_id": "T78",
              "tail_entity_id": "T75"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T82",
              "tail_entity_id": "T75"
            }
          ],
          "sentence_en": "The rapid advice guideline recommends DPP-4 inhibitors as one of the first-line treatment options for patients with type 2 diabetes, and believes that DPP-4 inhibitors can be used as a first-line alternative treatment drug in cases of metformin intolerance or contraindications. At the just-concluded 2017 CDS Annual Meeting, Professor Jia Weiping briefly introduced some of the contents of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 Edition)\" (hereinafter referred to as the 2017 Guidelines), which will be released soon. A major change in the hyperglycemia treatment process is to change the original first-line, second-line, and third-line drugs to monotherapy, dual and triple therapy, which is equivalent to further emphasizing the importance of metformin, because dual and triple therapy both recommend the addition of other drugs to metformin, and in monotherapy, the alternative drugs given when metformin is intolerant or contraindicated are α-glucosidase inhibitors and insulin secretagogues. Personally, I think that the reason why α-glucosidase inhibitors are recommended is that postprandial hyperglycemia (especially simple postprandial hyperglycemia) is very common in China, and insulin secretagogues are recommended because their glucose-lowering efficacy is comparable to that of metformin. The reason why DPP-4 inhibitors are not recommended is that they may be considered from the perspective of economy and availability, and on the other hand, their glucose-lowering efficacy may be slightly weaker. Coincidentally, at the 2017 CDS Annual Meeting, Professor Ji Linong's report entitled \"Strategies for Reaching Blood Glucose Targets: Initial Treatment of Type 2 Diabetes\" also analyzed the comparison between metformin and DPP-4 inhibitors when starting monotherapy. Three Chinese studies published in 2016-2017 comparing metformin with sitagliptin, alogliptin, and linagliptin all found that both low-dose and high-dose (1700 or 2000 mg/day) metformin treatment had better glucose-lowering efficacy than DPP-4 inhibitors."
        },
        {
          "sentence_id": "1",
          "sentence": "因此，纪教授的观点是，对于单药治疗患者，高剂量二甲双胍应作为常规起始治疗。",
          "start_idx": 577,
          "end_idx": 614,
          "entities": [
            {
              "entity_id": "T72",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, Professor Ji’s view is that for patients receiving monotherapy, high-dose metformin should be used as routine starting treatment."
        }
      ],
      "paragraph_en": "The rapid advice guideline recommends DPP-4 inhibitors as one of the first-line treatment options for patients with type 2 diabetes, and believes that DPP-4 inhibitors can be used as a first-line alternative treatment drug in cases of metformin intolerance or contraindications. At the just-concluded 2017 CDS Annual Meeting, Professor Jia Weiping briefly introduced some of the contents of the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 Edition)\" (hereinafter referred to as the 2017 Guidelines), which will be released soon. A major change in the hyperglycemia treatment process is to change the original first-line, second-line, and third-line drugs to monotherapy, dual and triple therapy, which is equivalent to further emphasizing the importance of metformin, because dual and triple therapy both recommend the addition of other drugs to metformin, and in monotherapy, the alternative drugs given when metformin is intolerant or contraindicated are α-glucosidase inhibitors and insulin secretagogues. Personally, I think that the reason why α-glucosidase inhibitors are recommended is that postprandial hyperglycemia (especially simple postprandial hyperglycemia) is very common in China, and insulin secretagogues are recommended because their glucose-lowering efficacy is comparable to that of metformin. The reason why DPP-4 inhibitors are not recommended is that they may be considered from the perspective of economy and availability, and on the other hand, their glucose-lowering efficacy may be slightly weaker. Coincidentally, at the 2017 CDS Annual Meeting, Professor Ji Linong's report entitled \"Strategies for Reaching Blood Glucose Targets: Initial Treatment of Type 2 Diabetes\" also analyzed the comparison between metformin and DPP-4 inhibitors when starting monotherapy. Three Chinese studies published in 2016-2017 comparing metformin with sitagliptin, alogliptin, and linagliptin all found that both low-dose and high-dose (1700 or 2000 mg/day) metformin treatment had better glucose-lowering efficacy than DPP-4 inhibitors. Therefore, Professor Ji's view is that for patients receiving monotherapy, high-dose metformin should be used as a routine initial treatment."
    },
    {
      "paragraph_id": "11",
      "paragraph": "(2)联合用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)联合用药",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(2) Combination therapy"
        }
      ],
      "paragraph_en": "(2) Combination therapy"
    },
    {
      "paragraph_id": "12",
      "paragraph": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的二线和三线治疗选择之一，指出在当二甲双胍或者其他降糖药物单药治疗后，如糖化血红蛋白水平仍未达标，可联合此类药物。2017版指南也同样将DPP-4抑制剂列为与二甲双胍进行二联或三联治疗的选择之一。在这一点上，两个指南并没有分歧，然而。从最新的国内研究证据来看，在二甲双胍高剂量(2000毫克/天)单药治疗的基础上，加用DPP-4抑制剂只能使糖化血红蛋白进一步下降约0-2%，而减重作用反而更差一些，而在欧美人群中进行的研究中，糖化血红蛋白进一步下降了约0.5%，这是否是降糖药物的又一个中国特色呢(前一个中国特色是α-糖苷酶抑制剂的“西方不亮东方亮”——本刊注)?不过，DPP-4抑制剂可以带来多重获益。我们或许不能单以降低糖化血红蛋白的能力论英雄。这些都还有待更多的研究来论证。毕竟这类药物进入我国临床只有短短几年而已。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂作为2型糖尿病患者的二线和三线治疗选择之一，指出在当二甲双胍或者其他降糖药物单药治疗后，如糖化血红蛋白水平仍未达标，可联合此类药物。2017版指南也同样将DPP-4抑制剂列为与二甲双胍进行二联或三联治疗的选择之一。在这一点上，两个指南并没有分歧，然而。从最新的国内研究证据来看，在二甲双胍高剂量(2000毫克/天)单药治疗的基础上，加用DPP-4抑制剂只能使糖化血红蛋白进一步下降约0-2%，而减重作用反而更差一些，而在欧美人群中进行的研究中，糖化血红蛋白进一步下降了约0.5%，这是否是降糖药物的又一个中国特色呢(前一个中国特色是α-糖苷酶抑制剂的“西方不亮东方亮”——本刊注)?不过，DPP-4抑制剂可以带来多重获益。",
          "start_idx": 0,
          "end_idx": 327,
          "entities": [
            {
              "entity_id": "T85",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T86",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T87",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 93,
              "end_idx": 101,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T88",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T89",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 156,
              "end_idx": 160,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T90",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 192,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T91",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 282,
              "end_idx": 290,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T92",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 310,
              "end_idx": 318,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T93",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T94",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T95",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 67,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T96",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 195,
              "end_idx": 201,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T97",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 238,
              "end_idx": 244,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T98",
              "entity": "2000毫克/天",
              "entity_type": "Amount",
              "start_idx": 164,
              "end_idx": 172,
              "entity_en": "2000 mg/day"
            },
            {
              "entity_id": "T99",
              "entity": "未达标",
              "entity_type": "Test_Value",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T100",
              "entity": "下降约0-2%",
              "entity_type": "Test_Value",
              "start_idx": 204,
              "end_idx": 211,
              "entity_en": "Decrease of about 0-2%"
            },
            {
              "entity_id": "T101",
              "entity": "下降了约0.5%",
              "entity_type": "Test_Value",
              "start_idx": 247,
              "end_idx": 255,
              "entity_en": "It has dropped by about 0.5%."
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R13",
              "head_entity_id": "T85",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T86",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R15",
              "head_entity_id": "T98",
              "tail_entity_id": "T89"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R16",
              "head_entity_id": "T94",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R17",
              "head_entity_id": "T95",
              "tail_entity_id": "T93"
            }
          ],
          "sentence_en": "The rapid advice guidelines recommend DPP-4 inhibitors as one of the second-line and third-line treatment options for patients with type 2 diabetes, pointing out that such drugs can be combined with metformin or other glucose-lowering drugs when the glycated hemoglobin level is still not up to standard. The 2017 version of the guidelines also lists DPP-4 inhibitors as one of the options for dual or triple therapy with metformin. On this point, the two guidelines do not disagree, however. From the latest domestic research evidence, on the basis of high-dose (2000 mg/day) metformin monotherapy, the addition of DPP-4 inhibitors can only further reduce glycated hemoglobin by about 0-2%, while the weight loss effect is even worse. In studies conducted in European and American populations, glycated hemoglobin further decreased by about 0.5%. Is this another Chinese characteristic of glucose-lowering drugs (the previous Chinese characteristic was the \"brightness in the east but not in the west\" of α-glucosidase inhibitors - this journal note)? However, DPP-4 inhibitors can bring multiple benefits."
        },
        {
          "sentence_id": "1",
          "sentence": "我们或许不能单以降低糖化血红蛋白的能力论英雄。",
          "start_idx": 327,
          "end_idx": 350,
          "entities": [
            {
              "entity_id": "T102",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 16,
              "entity_en": "Glycated hemoglobin"
            }
          ],
          "relations": [],
          "sentence_en": "We may not be able to judge a patient's success solely by his ability to lower glycated hemoglobin."
        },
        {
          "sentence_id": "2",
          "sentence": "这些都还有待更多的研究来论证。",
          "start_idx": 350,
          "end_idx": 365,
          "entities": [],
          "relations": [],
          "sentence_en": "These still need more research to prove."
        },
        {
          "sentence_id": "3",
          "sentence": "毕竟这类药物进入我国临床只有短短几年而已。",
          "start_idx": 365,
          "end_idx": 386,
          "entities": [],
          "relations": [],
          "sentence_en": "After all, this type of drug has only been used clinically in my country for a few years."
        }
      ],
      "paragraph_en": "The rapid advice guideline recommends DPP-4 inhibitors as one of the second-line and third-line treatment options for patients with type 2 diabetes, pointing out that such drugs can be combined after monotherapy with metformin or other glucose-lowering drugs, if the glycated hemoglobin level is still not up to standard. The 2017 version of the guideline also lists DPP-4 inhibitors as one of the options for dual or triple therapy with metformin. On this point, the two guidelines do not disagree, however. From the latest domestic research evidence, on the basis of high-dose (2000 mg/day) metformin monotherapy, the addition of DPP-4 inhibitors can only further reduce glycated hemoglobin by about 0-2%, and the weight loss effect is even worse. In studies conducted in European and American populations, glycated hemoglobin further decreased by about 0.5%. Is this another Chinese characteristic of glucose-lowering drugs (the previous Chinese characteristic was the \"brightness in the east but not in the west\" of α-glucosidase inhibitors - this journal note)? However, DPP-4 inhibitors can bring multiple benefits. We may not be able to judge heroes by their ability to reduce glycated hemoglobin alone. These still need more research to prove. After all, this type of drug has only been in clinical use in my country for a few years."
    },
    {
      "paragraph_id": "13",
      "paragraph": "(3)用法用量",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)用法用量",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(3) Usage and Dosage"
        }
      ],
      "paragraph_en": "(3) Usage and Dosage"
    },
    {
      "paragraph_id": "14",
      "paragraph": "快速建议指南推荐DPP-4抑制剂的剂量为说明中规定的常规使用剂量。临床应用共识则给出了更详细的肝肾功能不全患者的用法用量：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂的剂量为说明中规定的常规使用剂量。临床应用共识则给出了更详细的肝肾功能不全患者的用法用量：",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T103",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T104",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 53,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T105",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 47,
              "end_idx": 48,
              "entity_en": "liver"
            },
            {
              "entity_id": "T106",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 49,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R18",
              "head_entity_id": "T105",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R19",
              "head_entity_id": "T106",
              "tail_entity_id": "T104"
            }
          ],
          "sentence_en": "The rapid advice guideline recommends that the dosage of DPP-4 inhibitors be the conventional dosage specified in the instructions. The clinical application consensus provides more detailed usage and dosage for patients with liver and kidney dysfunction:"
        }
      ],
      "paragraph_en": "The rapid advice guideline recommends that the dosage of DPP-4 inhibitors be the conventional dosage specified in the instructions. The clinical application consensus provides more detailed usage and dosage for patients with liver and kidney dysfunction:"
    },
    {
      "paragraph_id": "17",
      "paragraph": "特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特殊情况",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Special circumstances"
        }
      ],
      "paragraph_en": "Special circumstances"
    },
    {
      "paragraph_id": "18",
      "paragraph": "(1)与胰岛素联用",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)与胰岛素联用",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T107",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "insulin"
            }
          ],
          "relations": [],
          "sentence_en": "(1) Combined with insulin"
        }
      ],
      "paragraph_en": "(1) Combined with insulin"
    },
    {
      "paragraph_id": "20",
      "paragraph": "(2)老年患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)老年患者",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(2) Elderly patients"
        }
      ],
      "paragraph_en": "(2) Elderly patients"
    },
    {
      "paragraph_id": "21",
      "paragraph": "快速建议指南推荐DPP-4抑制剂用于65岁以上的2型糖尿病患者的降糖治疗。其理由是，老年患者常常合并多种并发疾病，而DPP-4抑制剂具有良好的血糖控制效果和安全性，同时也指出，推荐使用常规剂量进行治疗，但如患者伴有肝或肾功能不全，则需要根据说明书进行剂量调整。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂用于65岁以上的2型糖尿病患者的降糖治疗。其理由是，老年患者常常合并多种并发疾病，而DPP-4抑制剂具有良好的血糖控制效果和安全性，同时也指出，推荐使用常规剂量进行治疗，但如患者伴有肝或肾功能不全，则需要根据说明书进行剂量调整。",
          "start_idx": 0,
          "end_idx": 130,
          "entities": [
            {
              "entity_id": "T108",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T109",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 66,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T110",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T111",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T112",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T113",
              "entity": "肝或肾功能不全",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 114,
              "entity_en": "Hepatic or renal impairment"
            },
            {
              "entity_id": "T114",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 107,
              "end_idx": 108,
              "entity_en": "liver"
            },
            {
              "entity_id": "T115",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 109,
              "end_idx": 110,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T111",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R21",
              "head_entity_id": "T112",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R22",
              "head_entity_id": "T114",
              "tail_entity_id": "T113"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R23",
              "head_entity_id": "T115",
              "tail_entity_id": "T113"
            }
          ],
          "sentence_en": "The rapid advice guideline recommends DPP-4 inhibitors for glucose-lowering treatment in patients with type 2 diabetes over the age of 65. The reason is that elderly patients often have multiple concurrent diseases, and DPP-4 inhibitors have good blood sugar control effects and safety. It also points out that conventional doses are recommended for treatment, but if the patient has liver or kidney dysfunction, the dose needs to be adjusted according to the instructions."
        }
      ],
      "paragraph_en": "The rapid advice guideline recommends DPP-4 inhibitors for glucose-lowering treatment in patients with type 2 diabetes over the age of 65. The reason is that elderly patients often have multiple concurrent diseases, and DPP-4 inhibitors have good blood sugar control effects and safety. It also points out that conventional doses are recommended for treatment, but if the patient has liver or kidney dysfunction, the dose needs to be adjusted according to the instructions."
    },
    {
      "paragraph_id": "22",
      "paragraph": "(3)超重/肥胖患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)超重/肥胖患者",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T116",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 5,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T117",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "obesity"
            }
          ],
          "relations": [],
          "sentence_en": "(3) Overweight/obese patients"
        }
      ],
      "paragraph_en": "(3) Overweight/obese patients"
    },
    {
      "paragraph_id": "23",
      "paragraph": "快速建议指南认为DPP-4抑制剂可用于超重/肥胖2型糖尿病患者的降糖治疗，理由是DPP-4抑制剂并不影响患者的体重。然而，如前所述，最新研究显示在二甲双胍治疗基础上加上DPP-4抑制剂，患者的体重减轻幅度反而变小了，其原因还需要进一步的研究来明确。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南认为DPP-4抑制剂可用于超重/肥胖2型糖尿病患者的降糖治疗，理由是DPP-4抑制剂并不影响患者的体重。",
          "start_idx": 0,
          "end_idx": 58,
          "entities": [
            {
              "entity_id": "T118",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T119",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 48,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T122",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T123",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T124",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T125",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Type 2"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R24",
              "head_entity_id": "T118",
              "tail_entity_id": "T122"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R25",
              "head_entity_id": "T118",
              "tail_entity_id": "T123"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R26",
              "head_entity_id": "T118",
              "tail_entity_id": "T124"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T125",
              "tail_entity_id": "T124"
            }
          ],
          "sentence_en": "The rapid advice guideline suggests that DPP-4 inhibitors can be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes, on the grounds that DPP-4 inhibitors do not affect the patient's weight."
        },
        {
          "sentence_id": "1",
          "sentence": "然而，如前所述，最新研究显示在二甲双胍治疗基础上加上DPP-4抑制剂，患者的体重减轻幅度反而变小了，其原因还需要进一步的研究来明确。",
          "start_idx": 58,
          "end_idx": 124,
          "entities": [
            {
              "entity_id": "T120",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T121",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 34,
              "entity_en": "DPP-4 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "However, as mentioned earlier, the latest research shows that when DPP-4 inhibitors are added to metformin treatment, patients' weight loss is reduced. The reason for this needs further research to clarify."
        }
      ],
      "paragraph_en": "The rapid advice guideline believes that DPP-4 inhibitors can be used for glucose-lowering treatment in overweight/obese patients with type 2 diabetes, on the grounds that DPP-4 inhibitors do not affect the patient's weight. However, as mentioned earlier, the latest study shows that when DPP-4 inhibitors are added to metformin treatment, the patient's weight loss is reduced, and the reason needs further research to clarify."
    },
    {
      "paragraph_id": "24",
      "paragraph": "(4)伴心血管疾病或心血管风险高的患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)伴心血管疾病或心血管风险高的患者",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T126",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T127",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R28",
              "head_entity_id": "T127",
              "tail_entity_id": "T126"
            }
          ],
          "sentence_en": "(4) Patients with cardiovascular disease or high cardiovascular risk"
        }
      ],
      "paragraph_en": "(4) Patients with cardiovascular disease or high cardiovascular risk"
    },
    {
      "paragraph_id": "25",
      "paragraph": "快速建议指南基于证据总结和专家意见，认为DPP-4抑制剂可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南基于证据总结和专家意见，认为DPP-4抑制剂可用于伴有心血管疾病或心血管事件风险的2型糖尿病患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T128",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 28,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T129",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 52,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T130",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T131",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 36,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T132",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T133",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 44,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T134",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 39,
              "end_idx": 42,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R29",
              "head_entity_id": "T128",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R30",
              "head_entity_id": "T128",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R31",
              "head_entity_id": "T132",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R32",
              "head_entity_id": "T131",
              "tail_entity_id": "T130"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R33",
              "head_entity_id": "T134",
              "tail_entity_id": "T133"
            }
          ],
          "sentence_en": "Based on evidence summary and expert opinion, the rapid advice guideline believes that DPP-4 inhibitors can be used for glucose-lowering treatment in patients with type 2 diabetes who are at risk of cardiovascular disease or cardiovascular events."
        }
      ],
      "paragraph_en": "Based on evidence summary and expert opinion, the rapid advice guideline believes that DPP-4 inhibitors can be used for glucose-lowering treatment in patients with type 2 diabetes who are at risk of cardiovascular disease or cardiovascular events."
    },
    {
      "paragraph_id": "26",
      "paragraph": "(5)复方制剂",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)复方制剂",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(5) Compound preparations"
        }
      ],
      "paragraph_en": "(5) Compound preparations"
    },
    {
      "paragraph_id": "27",
      "paragraph": "快速建议指南推荐复方制剂(DPP-4抑制剂和二甲双胍)用于2型糖尿病患者的起始降糖治疗，指出对于糖化血红蛋白>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4抑制剂和二甲双胍)进行起始治疗。不过就像前面提到的，这种用法可能还有待商榷。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐复方制剂(DPP-4抑制剂和二甲双胍)用于2型糖尿病患者的起始降糖治疗，指出对于糖化血红蛋白>7.5%的首次治疗患者，推荐使用复方制剂(DPP-4抑制剂和二甲双胍)进行起始治疗。",
          "start_idx": 0,
          "end_idx": 97,
          "entities": [
            {
              "entity_id": "T135",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 21,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T136",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 26,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T137",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 84,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T138",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 89,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T139",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T140",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T141",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 54,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T142",
              "entity": ">7.5%",
              "entity_type": "Test_Value",
              "start_idx": 54,
              "end_idx": 59,
              "entity_en": ">7.5%"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R34",
              "head_entity_id": "T135",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R35",
              "head_entity_id": "T136",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R36",
              "head_entity_id": "T141",
              "tail_entity_id": "T139"
            }
          ],
          "sentence_en": "The rapid advice guideline recommends combination preparations (DPP-4 inhibitors and metformin) for the initial glucose-lowering treatment of patients with type 2 diabetes, pointing out that for patients with glycated hemoglobin >7.5% who are receiving treatment for the first time, combination preparations (DPP-4 inhibitors and metformin) are recommended for initial treatment."
        },
        {
          "sentence_id": "1",
          "sentence": "不过就像前面提到的，这种用法可能还有待商榷。",
          "start_idx": 97,
          "end_idx": 119,
          "entities": [],
          "relations": [],
          "sentence_en": "However, as mentioned earlier, this usage may still be debatable."
        }
      ],
      "paragraph_en": "The rapid advice guideline recommends combination drugs (DPP-4 inhibitors and metformin) for the initial glucose-lowering treatment of patients with type 2 diabetes, and points out that for patients with glycated hemoglobin>7.5% who are receiving treatment for the first time, combination drugs (DPP-4 inhibitors and metformin) are recommended for initial treatment. However, as mentioned above, this use may still be debatable."
    },
    {
      "paragraph_id": "28",
      "paragraph": "(6)超敏反应",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(6)超敏反应",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": [],
          "sentence_en": "(6) Hypersensitivity reaction"
        }
      ],
      "paragraph_en": "(6) Hypersensitivity reaction"
    },
    {
      "paragraph_id": "29",
      "paragraph": "临床应用共识指出西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和剥脱性皮肤损害，如怀疑发生超敏反应时应停用；维格列汀尽管在临床中未观察到皮肤损伤发生率升高，但在合并糖尿病皮肤并发症的患者中经验有限，建议观察皮肤病变，如水疱、皮疹或溃疡等情况；阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应时应停用；沙格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)，怀疑时应停用；利格列汀在临床研究中也报告有高敏反应，如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识指出西格列汀在上市后发现有严重超敏反应，包括过敏反应、血管性水肿和剥脱性皮肤损害，如怀疑发生超敏反应时应停用；维格列汀尽管在临床中未观察到皮肤损伤发生率升高，但在合并糖尿病皮肤并发症的患者中经验有限，建议观察皮肤病变，如水疱、皮疹或溃疡等情况；阿格列汀在上市后发现严重皮肤不良反应，如怀疑发生严重过敏反应时应停用；沙格列汀上市后有报告严重超敏反应(包括速发过敏反应和血管性水肿)，怀疑时应停用；利格列汀在临床研究中也报告有高敏反应，如荨麻疹、血管性水肿、局部皮肤剥脱或支气管高敏反应。",
          "start_idx": 0,
          "end_idx": 248,
          "entities": [
            {
              "entity_id": "T143",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T144",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T145",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 132,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T146",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T147",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T148",
              "entity": "糖尿病皮肤并发症",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 97,
              "entity_en": "Skin complications of diabetes"
            },
            {
              "entity_id": "T149",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T150",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Allergic reactions"
            },
            {
              "entity_id": "T151",
              "entity": "血管性水肿",
              "entity_type": "ADE",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "Angioedema"
            },
            {
              "entity_id": "T152",
              "entity": "剥脱性皮肤损害",
              "entity_type": "ADE",
              "start_idx": 39,
              "end_idx": 46,
              "entity_en": "Exfoliative skin lesions"
            },
            {
              "entity_id": "T153",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 52,
              "end_idx": 56,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T154",
              "entity": "皮肤损伤发生率升高",
              "entity_type": "ADE",
              "start_idx": 75,
              "end_idx": 84,
              "entity_en": "Increased incidence of skin lesions"
            },
            {
              "entity_id": "T155",
              "entity": "皮肤病变",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 114,
              "entity_en": "Skin lesions"
            },
            {
              "entity_id": "T156",
              "entity": "水疱",
              "entity_type": "ADE",
              "start_idx": 116,
              "end_idx": 118,
              "entity_en": "Blisters"
            },
            {
              "entity_id": "T157",
              "entity": "皮疹",
              "entity_type": "ADE",
              "start_idx": 119,
              "end_idx": 121,
              "entity_en": "rash"
            },
            {
              "entity_id": "T158",
              "entity": "溃疡",
              "entity_type": "ADE",
              "start_idx": 122,
              "end_idx": 124,
              "entity_en": "ulcer"
            },
            {
              "entity_id": "T159",
              "entity": "皮肤不良反应",
              "entity_type": "ADE",
              "start_idx": 140,
              "end_idx": 146,
              "entity_en": "Skin adverse reactions"
            },
            {
              "entity_id": "T160",
              "entity": "过敏反应",
              "entity_type": "ADE",
              "start_idx": 154,
              "end_idx": 158,
              "entity_en": "Allergic reactions"
            },
            {
              "entity_id": "T161",
              "entity": "超敏反应",
              "entity_type": "ADE",
              "start_idx": 175,
              "end_idx": 179,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T162",
              "entity": "速发过敏反应",
              "entity_type": "ADE",
              "start_idx": 182,
              "end_idx": 188,
              "entity_en": "Allergic reaction"
            },
            {
              "entity_id": "T163",
              "entity": "血管性水肿",
              "entity_type": "ADE",
              "start_idx": 189,
              "end_idx": 194,
              "entity_en": "Angioedema"
            },
            {
              "entity_id": "T164",
              "entity": "高敏反应",
              "entity_type": "ADE",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Hypersensitivity reactions"
            },
            {
              "entity_id": "T165",
              "entity": "荨麻疹",
              "entity_type": "ADE",
              "start_idx": 223,
              "end_idx": 226,
              "entity_en": "Urticaria"
            },
            {
              "entity_id": "T166",
              "entity": "血管性水肿",
              "entity_type": "ADE",
              "start_idx": 227,
              "end_idx": 232,
              "entity_en": "Angioedema"
            },
            {
              "entity_id": "T167",
              "entity": "局部皮肤剥脱",
              "entity_type": "ADE",
              "start_idx": 233,
              "end_idx": 239,
              "entity_en": "Local skin peeling"
            },
            {
              "entity_id": "T168",
              "entity": "支气管高敏反应",
              "entity_type": "ADE",
              "start_idx": 240,
              "end_idx": 247,
              "entity_en": "Bronchial hypersensitivity reaction"
            },
            {
              "entity_id": "T169",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "serious"
            },
            {
              "entity_id": "T170",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 138,
              "end_idx": 140,
              "entity_en": "serious"
            },
            {
              "entity_id": "T171",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 152,
              "end_idx": 154,
              "entity_en": "serious"
            },
            {
              "entity_id": "T172",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 173,
              "end_idx": 175,
              "entity_en": "serious"
            },
            {
              "entity_id": "T173",
              "entity": "皮肤",
              "entity_type": "Anatomy",
              "start_idx": 92,
              "end_idx": 94,
              "entity_en": "skin"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R37",
              "head_entity_id": "T149",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R38",
              "head_entity_id": "T150",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R39",
              "head_entity_id": "T151",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R40",
              "head_entity_id": "T152",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R41",
              "head_entity_id": "T153",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R42",
              "head_entity_id": "T159",
              "tail_entity_id": "T145"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R43",
              "head_entity_id": "T160",
              "tail_entity_id": "T145"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R44",
              "head_entity_id": "T161",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R45",
              "head_entity_id": "T162",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R46",
              "head_entity_id": "T163",
              "tail_entity_id": "T146"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R47",
              "head_entity_id": "T165",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R48",
              "head_entity_id": "T164",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R49",
              "head_entity_id": "T166",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R50",
              "head_entity_id": "T167",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R51",
              "head_entity_id": "T168",
              "tail_entity_id": "T147"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R52",
              "head_entity_id": "T173",
              "tail_entity_id": "T148"
            }
          ],
          "sentence_en": "The consensus on clinical application pointed out that severe hypersensitivity reactions, including allergic reactions, angioedema and exfoliative skin lesions, were found in sitagliptin after it was marketed. If a hypersensitivity reaction is suspected, the drug should be discontinued. Although no increased incidence of skin damage was observed in clinical practice with vildagliptin, there is limited experience in patients with diabetic skin complications, and it is recommended to observe skin lesions, such as blisters, rashes or ulcers. Severe adverse skin reactions were found in alogliptin after it was marketed. If a severe allergic reaction is suspected, the drug should be discontinued. Severe hypersensitivity reactions (including anaphylactic reactions and angioedema) have been reported in saxagliptin after it was marketed. If suspected, the drug should be discontinued. Hypersensitivity reactions, such as urticaria, angioedema, local skin exfoliation or bronchial hypersensitivity reactions, have also been reported in clinical studies with linagliptin."
        }
      ],
      "paragraph_en": "The consensus on clinical application pointed out that severe hypersensitivity reactions, including allergic reactions, angioedema and exfoliative skin lesions, were found in sitagliptin after it was marketed. If a hypersensitivity reaction is suspected, the drug should be discontinued. Although no increased incidence of skin damage was observed in clinical practice with vildagliptin, there is limited experience in patients with diabetic skin complications, and it is recommended to observe skin lesions, such as blisters, rashes or ulcers. Severe adverse skin reactions were found in alogliptin after it was marketed. If a severe allergic reaction is suspected, the drug should be discontinued. Severe hypersensitivity reactions (including anaphylactic reactions and angioedema) have been reported in saxagliptin after it was marketed. If suspected, the drug should be discontinued. Hypersensitivity reactions, such as urticaria, angioedema, local skin exfoliation or bronchial hypersensitivity reactions, have also been reported in clinical studies with linagliptin."
    },
    {
      "paragraph_id": "30",
      "paragraph": "(7)药物相互作用",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(7)药物相互作用",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "(7) Drug interactions"
        }
      ],
      "paragraph_en": "(7) Drug interactions"
    },
    {
      "paragraph_id": "31",
      "paragraph": "西格列汀与磺脲类药物合用时低血糖风险增加，需适当减少磺脲类剂量；利格列汀与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类剂量；沙格列汀与酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦和泰利霉素等合用时，应将剂量限制为2.5毫克/天。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "西格列汀与磺脲类药物合用时低血糖风险增加，需适当减少磺脲类剂量；利格列汀与胰岛素、磺脲类合用时低血糖风险增加，需适当减少胰岛素和磺脲类剂量；沙格列汀与酮康唑、阿扎那韦、克拉霉素、茚地那韦、伊曲康唑、奈法唑酮、奈非那韦、利托那韦、沙奎那韦和泰利霉素等合用时，应将剂量限制为2.5毫克/天。",
          "start_idx": 0,
          "end_idx": 143,
          "entities": [
            {
              "entity_id": "T174",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T175",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 10,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T176",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 26,
              "end_idx": 29,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T177",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T178",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T179",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 44,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T180",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T181",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T182",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 74,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T183",
              "entity": "酮康唑",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "Ketoconazole"
            },
            {
              "entity_id": "T184",
              "entity": "阿扎那韦",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 83,
              "entity_en": "Atazanavir"
            },
            {
              "entity_id": "T185",
              "entity": "克拉霉素",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 88,
              "entity_en": "Clarithromycin"
            },
            {
              "entity_id": "T186",
              "entity": "茚地那韦",
              "entity_type": "Drug",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Indinavir"
            },
            {
              "entity_id": "T187",
              "entity": "伊曲康唑",
              "entity_type": "Drug",
              "start_idx": 94,
              "end_idx": 98,
              "entity_en": "Itraconazole"
            },
            {
              "entity_id": "T188",
              "entity": "奈法唑酮",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "Nefazodone"
            },
            {
              "entity_id": "T189",
              "entity": "奈非那韦",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108,
              "entity_en": "Nelfinavir"
            },
            {
              "entity_id": "T190",
              "entity": "利托那韦",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113,
              "entity_en": "Ritonavir"
            },
            {
              "entity_id": "T191",
              "entity": "沙奎那韦",
              "entity_type": "Drug",
              "start_idx": 114,
              "end_idx": 118,
              "entity_en": "Saquinavir"
            },
            {
              "entity_id": "T192",
              "entity": "泰利霉素",
              "entity_type": "Drug",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "Telithromycin"
            },
            {
              "entity_id": "T193",
              "entity": "低血糖风险增加",
              "entity_type": "ADE",
              "start_idx": 13,
              "end_idx": 20,
              "entity_en": "Increased risk of hypoglycemia"
            },
            {
              "entity_id": "T194",
              "entity": "低血糖风险增加",
              "entity_type": "ADE",
              "start_idx": 47,
              "end_idx": 54,
              "entity_en": "Increased risk of hypoglycemia"
            },
            {
              "entity_id": "T195",
              "entity": "2.5毫克/天",
              "entity_type": "Amount",
              "start_idx": 135,
              "end_idx": 142,
              "entity_en": "2.5 mg/day"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R53",
              "head_entity_id": "T193",
              "tail_entity_id": "T174"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R54",
              "head_entity_id": "T193",
              "tail_entity_id": "T175"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R55",
              "head_entity_id": "T194",
              "tail_entity_id": "T177"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R56",
              "head_entity_id": "T194",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R57",
              "head_entity_id": "T194",
              "tail_entity_id": "T179"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R58",
              "head_entity_id": "T195",
              "tail_entity_id": "T182"
            }
          ],
          "sentence_en": "When sitagliptin is used in combination with sulfonylureas, the risk of hypoglycemia increases, and the dose of sulfonylureas needs to be appropriately reduced; when linagliptin is used in combination with insulin and sulfonylureas, the risk of hypoglycemia increases, and the doses of insulin and sulfonylureas need to be appropriately reduced; when saxagliptin is used in combination with ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir and telithromycin, the dose should be limited to 2.5 mg/day."
        }
      ],
      "paragraph_en": "When sitagliptin is used in combination with sulfonylureas, the risk of hypoglycemia increases, and the dose of sulfonylureas needs to be appropriately reduced; when linagliptin is used in combination with insulin and sulfonylureas, the risk of hypoglycemia increases, and the doses of insulin and sulfonylureas need to be appropriately reduced; when saxagliptin is used in combination with ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir and telithromycin, the dose should be limited to 2.5 mg/day."
    },
    {
      "paragraph_id": "32",
      "paragraph": "GLP一1受体激动剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "GLP一1受体激动剂：(《基于胰高血糖素样肽1降糖药物的临床应用共识》/《基于肠促胰素的药物治疗临床应用的快速建议指南》)",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T196",
              "entity": "GLP一1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 10,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [],
          "sentence_en": "GLP-1 receptor agonists: (\"Consensus on the Clinical Application of Glucagon-like Peptide 1-based Hypoglycemic Drugs\"/\"Quick Recommendation Guidelines for the Clinical Application of Incretin-based Drug Therapy\")"
        }
      ],
      "paragraph_en": "GLP-1 receptor agonists: (\"Consensus on the Clinical Application of Glucagon-like Peptide 1-based Hypoglycemic Drugs\"/\"Quick Recommendation Guidelines for the Clinical Application of Incretin-based Drug Therapy\")"
    },
    {
      "paragraph_id": "33",
      "paragraph": "由于GLP一1受体广泛分布在胰岛细胞、胃肠、肺、脑、肾脏、下丘脑、心血管系统、肝脏、脂肪组织和骨骼肌，所以GLP-1除了能促进胰岛素分泌和抑制胰高血糖素分泌之外，还具有延缓胃排空和肠蠕动、抑制食欲、增加饱腹感、降压、降脂、保护肾脏等多方面的作用。也正因为如此，GLP-1受体激动剂类药物近年来备受关注和推崇，需要注射给药这一原本的短板，也随着每周一次的超长效制剂出现而得到弥补，每半月或每月给药一次的制剂也正在研发中，这类药物目前来看简直完美。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于GLP一1受体广泛分布在胰岛细胞、胃肠、肺、脑、肾脏、下丘脑、心血管系统、肝脏、脂肪组织和骨骼肌，所以GLP-1除了能促进胰岛素分泌和抑制胰高血糖素分泌之外，还具有延缓胃排空和肠蠕动、抑制食欲、增加饱腹感、降压、降脂、保护肾脏等多方面的作用。",
          "start_idx": 0,
          "end_idx": 123,
          "entities": [],
          "relations": [],
          "sentence_en": "Since GLP-1 receptors are widely distributed in pancreatic islet cells, gastrointestinal tract, lungs, brain, kidneys, hypothalamus, cardiovascular system, liver, adipose tissue and skeletal muscle, GLP-1 can not only promote insulin secretion and inhibit glucagon secretion, but also has many functions such as delaying gastric emptying and intestinal motility, suppressing appetite, increasing satiety, lowering blood pressure, lowering blood lipids, and protecting the kidneys."
        },
        {
          "sentence_id": "1",
          "sentence": "也正因为如此，GLP-1受体激动剂类药物近年来备受关注和推崇，需要注射给药这一原本的短板，也随着每周一次的超长效制剂出现而得到弥补，每半月或每月给药一次的制剂也正在研发中，这类药物目前来看简直完美。",
          "start_idx": 123,
          "end_idx": 222,
          "entities": [
            {
              "entity_id": "T197",
              "entity": "GLP-1受体激动剂类药物",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 20,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [],
          "sentence_en": "It is for this reason that GLP-1 receptor agonist drugs have received much attention and praise in recent years. The original shortcoming of requiring injection for administration has been compensated with the emergence of ultra-long-acting preparations that can be administered once a week. Preparations that can be administered once every half month or month are also under development. This type of drug is simply perfect at the moment."
        }
      ],
      "paragraph_en": "Since GLP-1 receptors are widely distributed in pancreatic islet cells, gastrointestinal tract, lungs, brain, kidneys, hypothalamus, cardiovascular system, liver, adipose tissue and skeletal muscle, GLP-1 can not only promote insulin secretion and inhibit glucagon secretion, but also has many functions such as delaying gastric emptying and intestinal motility, suppressing appetite, increasing satiety, lowering blood pressure, lowering lipids, and protecting kidneys. It is precisely because of this that GLP-1 receptor agonist drugs have received much attention and praise in recent years. The original shortcoming of injection administration has also been compensated with the emergence of ultra-long-acting preparations once a week. Preparations that can be administered every half month or month are also under development. This type of drug is simply perfect at present."
    },
    {
      "paragraph_id": "34",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Target Group"
        }
      ],
      "paragraph_en": "Target Group"
    },
    {
      "paragraph_id": "35",
      "paragraph": "临床应用共识指出，GLP-1受体激动剂适用于成人2型糖尿病患者，其中艾塞那肽目前国内适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者，而在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类以及基础胰岛素联合使用等；利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用，而在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍+磺脲类或与二甲双胍+噻唑烷二酮类或与胰岛素联合应用的适应证等。2017版指南同样将GLP-1受体激动剂列为可与二甲双胍进行二联或三联治疗的注射类药物之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识指出，GLP-1受体激动剂适用于成人2型糖尿病患者，其中艾塞那肽目前国内适用于单用二甲双胍、磺脲类，以及二甲双胍合用磺脲类，而血糖仍控制不佳的患者，而在国外，艾塞那肽还可与噻唑烷二酮类、二甲双胍合用磺脲类、二甲双胍合用噻唑烷二酮类以及基础胰岛素联合使用等；利拉鲁肽在国内适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用，而在国外，利拉鲁肽在此应用基础上还有单药使用，与二甲双胍+磺脲类或与二甲双胍+噻唑烷二酮类或与胰岛素联合应用的适应证等。",
          "start_idx": 0,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T198",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 19,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T199",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T200",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T201",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T202",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T203",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T204",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 89,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T205",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 98,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T206",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 99,
              "end_idx": 103,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T207",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 105,
              "end_idx": 108,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T208",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T209",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 121,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T210",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 123,
              "end_idx": 128,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T211",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 134,
              "end_idx": 138,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T212",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 150,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T213",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 156,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T214",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 182,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T215",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 183,
              "end_idx": 188,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T216",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 198,
              "end_idx": 202,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T217",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 217,
              "end_idx": 221,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T218",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 222,
              "end_idx": 225,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T219",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 227,
              "end_idx": 231,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T220",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 238,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T221",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 240,
              "end_idx": 243,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T224",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T225",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T226",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 69,
              "end_idx": 71,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T227",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 166,
              "end_idx": 168,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T228",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T229",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 169,
              "end_idx": 173,
              "entity_en": "Poor control"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R59",
              "head_entity_id": "T225",
              "tail_entity_id": "T224"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R60",
              "head_entity_id": "T226",
              "tail_entity_id": "T224"
            }
          ],
          "sentence_en": "The consensus on clinical application points out that GLP-1 receptor agonists are suitable for adult patients with type 2 diabetes. Among them, exenatide is currently suitable for patients in China who still have poor blood sugar control despite the use of metformin alone, sulfonylureas, and metformin combined with sulfonylureas. In foreign countries, exenatide can also be used in combination with thiazolidinediones, metformin combined with sulfonylureas, metformin combined with thiazolidinediones, and basal insulin. Liraglutide is suitable for patients in China whose blood sugar control is still poor after the maximum tolerable dose of metformin or sulfonylureas, and is used in combination with metformin or sulfonylureas. In foreign countries, liraglutide also has indications for single-drug use, combined with metformin + sulfonylureas, or metformin + thiazolidinediones, or combined with insulin."
        },
        {
          "sentence_id": "1",
          "sentence": "2017版指南同样将GLP-1受体激动剂列为可与二甲双胍进行二联或三联治疗的注射类药物之一。",
          "start_idx": 253,
          "end_idx": 299,
          "entities": [
            {
              "entity_id": "T222",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 20,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T223",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Metformin"
            }
          ],
          "relations": [],
          "sentence_en": "The 2017 guidelines also list GLP-1 receptor agonists as one of the injectable drugs that can be used in dual or triple therapy with metformin."
        }
      ],
      "paragraph_en": "The consensus on clinical application points out that GLP-1 receptor agonists are suitable for adult patients with type 2 diabetes. Exenatide is currently suitable for patients with poor blood sugar control despite single use of metformin, sulfonylureas, and metformin combined with sulfonylureas in China. In foreign countries, exenatide can also be used in combination with thiazolidinediones, metformin combined with sulfonylureas, metformin combined with thiazolidinediones, and basal insulin. Liraglutide is suitable for patients with poor blood sugar control after treatment with the maximum tolerated dose of metformin or sulfonylurea alone in China, and can be used in combination with metformin or sulfonylureas. In foreign countries, liraglutide has indications for single use, combined with metformin + sulfonylureas or metformin + thiazolidinediones or insulin. The 2017 version of the guidelines also lists GLP-1 receptor agonists as one of the injectable drugs that can be used in dual or triple therapy with metformin."
    },
    {
      "paragraph_id": "36",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Clinical Usage"
        }
      ],
      "paragraph_en": "Clinical Usage"
    },
    {
      "paragraph_id": "37",
      "paragraph": "临床应用共识推荐参考药品说明书使用。目前，两种GLP-1受体激动剂不仅价格昂贵，而且尚未被纳入医保，因此尽管能够带来多重获益，但临床上仍主要被用于其他降糖药物无法有效控糖的“顽固”患者和经济条件好的患者。我们也期待着这类药物尽快被纳入医保，让更多患者从中获益。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识推荐参考药品说明书使用。",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [],
          "relations": [],
          "sentence_en": "The clinical application consensus recommends using the drug instructions."
        },
        {
          "sentence_id": "1",
          "sentence": "目前，两种GLP-1受体激动剂不仅价格昂贵，而且尚未被纳入医保，因此尽管能够带来多重获益，但临床上仍主要被用于其他降糖药物无法有效控糖的“顽固”患者和经济条件好的患者。",
          "start_idx": 18,
          "end_idx": 102,
          "entities": [
            {
              "entity_id": "T230",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 15,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [],
          "sentence_en": "At present, the two GLP-1 receptor agonists are not only expensive, but have not yet been included in medical insurance. Therefore, despite their multiple benefits, they are still mainly used in clinical practice for \"stubborn\" patients who cannot effectively control blood sugar with other hypoglycemic drugs and patients with good economic conditions."
        },
        {
          "sentence_id": "2",
          "sentence": "我们也期待着这类药物尽快被纳入医保，让更多患者从中获益。",
          "start_idx": 102,
          "end_idx": 130,
          "entities": [],
          "relations": [],
          "sentence_en": "We also look forward to this type of drug being included in medical insurance as soon as possible so that more patients can benefit from it."
        }
      ],
      "paragraph_en": "The consensus on clinical application recommends referring to the drug instructions for use. Currently, the two GLP-1 receptor agonists are not only expensive, but have not yet been included in medical insurance. Therefore, despite the multiple benefits they can bring, they are still mainly used in the clinic for \"stubborn\" patients who cannot effectively control their blood sugar with other hypoglycemic drugs and patients with good economic conditions. We also look forward to this type of drug being included in medical insurance as soon as possible so that more patients can benefit from it."
    },
    {
      "paragraph_id": "38",
      "paragraph": "艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，因此临床应用共识建议医生应当告知患者急性胰腺炎的特征性症状，如怀疑发生了胰腺炎。应该立即停用。此外，GLP-1受体激动剂与磺脲类药物合用时低血糖发生率升高，建议适当减少磺脲类药物剂量以减少低血糖风险，当联合使用GLP-1受体激动剂与磺脲类药物时，医生应告知患者在驾驶或操作机械时采取必要措施以防止发生低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "艾塞那肽和利拉鲁肽使用中有少数急性胰腺炎病例报道，因此临床应用共识建议医生应当告知患者急性胰腺炎的特征性症状，如怀疑发生了胰腺炎。应该立即停用。此外，GLP-1受体激动剂与磺脲类药物合用时低血糖发生率升高，建议适当减少磺脲类药物剂量以减少低血糖风险，当联合使用GLP-1受体激动剂与磺脲类药物时，医生应告知患者在驾驶或操作机械时采取必要措施以防止发生低血糖。",
          "start_idx": 0,
          "end_idx": 179,
          "entities": [
            {
              "entity_id": "T231",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T232",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T233",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 85,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T234",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 91,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T235",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 114,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T236",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 140,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T237",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 146,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T238",
              "entity": "急性胰腺炎",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "Acute pancreatitis"
            },
            {
              "entity_id": "T239",
              "entity": "急性胰腺炎",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 48,
              "entity_en": "Acute pancreatitis"
            },
            {
              "entity_id": "T240",
              "entity": "胰腺炎",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 64,
              "entity_en": "pancreatitis"
            },
            {
              "entity_id": "T241",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "pancreas"
            },
            {
              "entity_id": "T242",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "pancreas"
            },
            {
              "entity_id": "T243",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "pancreas"
            },
            {
              "entity_id": "T244",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 94,
              "end_idx": 97,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T245",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 119,
              "end_idx": 122,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T246",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 175,
              "end_idx": 178,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R61",
              "head_entity_id": "T231",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R62",
              "head_entity_id": "T232",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R63",
              "head_entity_id": "T244",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R64",
              "head_entity_id": "T244",
              "tail_entity_id": "T234"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R65",
              "head_entity_id": "T245",
              "tail_entity_id": "T235"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R66",
              "head_entity_id": "T246",
              "tail_entity_id": "T236"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R67",
              "head_entity_id": "T246",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R68",
              "head_entity_id": "T241",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R69",
              "head_entity_id": "T242",
              "tail_entity_id": "T239"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R70",
              "head_entity_id": "T243",
              "tail_entity_id": "T240"
            }
          ],
          "sentence_en": "There have been a few reports of acute pancreatitis during the use of exenatide and liraglutide, so the consensus on clinical application recommends that doctors should inform patients of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, it should be discontinued immediately. In addition, the incidence of hypoglycemia increases when GLP-1 receptor agonists are used in combination with sulfonylureas. It is recommended to appropriately reduce the dose of sulfonylureas to reduce the risk of hypoglycemia. When GLP-1 receptor agonists are used in combination with sulfonylureas, doctors should inform patients to take necessary measures to prevent hypoglycemia when driving or operating machinery."
        }
      ],
      "paragraph_en": "There have been a few reports of acute pancreatitis during the use of exenatide and liraglutide, so the consensus on clinical application recommends that doctors should inform patients of the characteristic symptoms of acute pancreatitis. If pancreatitis is suspected, it should be discontinued immediately. In addition, the incidence of hypoglycemia increases when GLP-1 receptor agonists are used in combination with sulfonylureas. It is recommended to appropriately reduce the dose of sulfonylureas to reduce the risk of hypoglycemia. When GLP-1 receptor agonists are used in combination with sulfonylureas, doctors should inform patients to take necessary measures to prevent hypoglycemia when driving or operating machinery."
    },
    {
      "paragraph_id": "39",
      "paragraph": "特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特殊情况",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Special circumstances"
        }
      ],
      "paragraph_en": "Special circumstances"
    },
    {
      "paragraph_id": "40",
      "paragraph": "(1)不适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)不适用人群",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": [],
          "sentence_en": "(1) Not applicable to people"
        }
      ],
      "paragraph_en": "(1) Not applicable to people"
    },
    {
      "paragraph_id": "41",
      "paragraph": "临床应用共识给出了以下几类不适宜使用GLP-1受体激动剂的患者：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床应用共识给出了以下几类不适宜使用GLP-1受体激动剂的患者：",
          "start_idx": 0,
          "end_idx": 32,
          "entities": [
            {
              "entity_id": "T247",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 28,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [],
          "sentence_en": "The clinical application consensus provides the following categories of patients who are not suitable for the use of GLP-1 receptor agonists:"
        }
      ],
      "paragraph_en": "The clinical application consensus provides the following categories of patients who are not suitable for the use of GLP-1 receptor agonists:"
    },
    {
      "paragraph_id": "42",
      "paragraph": "·GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·GLP-1受体激动剂不能替代胰岛素，不适用于1型糖尿病患者或糖尿病酮症酸中毒的治疗。",
          "start_idx": 0,
          "end_idx": 43,
          "entities": [
            {
              "entity_id": "T248",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 11,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T249",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T250",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 28,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T251",
              "entity": "糖尿病酮症酸中毒",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 39,
              "entity_en": "Diabetic ketoacidosis"
            },
            {
              "entity_id": "T252",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "Type 1"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R71",
              "head_entity_id": "T252",
              "tail_entity_id": "T250"
            }
          ],
          "sentence_en": "GLP-1 receptor agonists are not a substitute for insulin and are not suitable for the treatment of patients with type 1 diabetes or diabetic ketoacidosis."
        }
      ],
      "paragraph_en": "GLP-1 receptor agonists are not a substitute for insulin and are not suitable for the treatment of patients with type 1 diabetes or diabetic ketoacidosis."
    },
    {
      "paragraph_id": "43",
      "paragraph": "·严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·严重胃肠道疾病患者、妊娠期和哺乳期妇女以及儿童不推荐使用。",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T253",
              "entity": "胃肠道疾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Gastrointestinal disorders"
            },
            {
              "entity_id": "T254",
              "entity": "胃",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "Stomach"
            },
            {
              "entity_id": "T255",
              "entity": "肠道",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "Intestinal"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R72",
              "head_entity_id": "T254",
              "tail_entity_id": "T253"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T255",
              "tail_entity_id": "T253"
            }
          ],
          "sentence_en": "Not recommended for patients with severe gastrointestinal diseases, pregnant and lactating women, and children."
        }
      ],
      "paragraph_en": "Not recommended for patients with severe gastrointestinal diseases, pregnant and lactating women, and children."
    },
    {
      "paragraph_id": "44",
      "paragraph": "·艾塞那肽有罕见肾功能改变报告，不推荐用于终末期肾病或严重肾功能不全患者；利拉鲁肽由于经验有限，也不推荐用于肾脏终末期患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·艾塞那肽有罕见肾功能改变报告，不推荐用于终末期肾病或严重肾功能不全患者；利拉鲁肽由于经验有限，也不推荐用于肾脏终末期患者。",
          "start_idx": 0,
          "end_idx": 62,
          "entities": [
            {
              "entity_id": "T256",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T257",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T258",
              "entity": "肾功能改变",
              "entity_type": "ADE",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Changes in renal function"
            },
            {
              "entity_id": "T259",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T260",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T261",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 25,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T262",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 30,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T263",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 24,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T264",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "serious"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R74",
              "head_entity_id": "T258",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R75",
              "head_entity_id": "T261",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R76",
              "head_entity_id": "T263",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R77",
              "head_entity_id": "T262",
              "tail_entity_id": "T260"
            }
          ],
          "sentence_en": "Exenatide has rare reports of changes in renal function and is not recommended for use in patients with end-stage renal disease or severe renal impairment. Liraglutide is also not recommended for use in patients with end-stage renal disease due to limited experience."
        }
      ],
      "paragraph_en": "Exenatide has rare reports of changes in renal function and is not recommended for use in patients with end-stage renal disease or severe renal impairment. Liraglutide is also not recommended for use in patients with end-stage renal disease due to limited experience."
    },
    {
      "paragraph_id": "45",
      "paragraph": "·利拉鲁肽在纽约心脏病学会(NYHA)分级l-II级的充血性心力衰竭的患者中的治疗经验有限，尚无在III一IV级充血性心力衰竭患者中的应用经验。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·利拉鲁肽在纽约心脏病学会(NYHA)分级l-II级的充血性心力衰竭的患者中的治疗经验有限，尚无在III一IV级充血性心力衰竭患者中的应用经验。",
          "start_idx": 0,
          "end_idx": 72,
          "entities": [
            {
              "entity_id": "T265",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T266",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 34,
              "entity_en": "Congestive heart failure"
            },
            {
              "entity_id": "T267",
              "entity": "充血性心力衰竭",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 63,
              "entity_en": "Congestive heart failure"
            },
            {
              "entity_id": "T268",
              "entity": "l-II级",
              "entity_type": "Class",
              "start_idx": 21,
              "end_idx": 26,
              "entity_en": "Level l-II"
            },
            {
              "entity_id": "T269",
              "entity": "III一IV级",
              "entity_type": "Class",
              "start_idx": 49,
              "end_idx": 56,
              "entity_en": "Level III-IV"
            },
            {
              "entity_id": "T270",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 30,
              "end_idx": 31,
              "entity_en": "Heart"
            },
            {
              "entity_id": "T271",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 59,
              "end_idx": 60,
              "entity_en": "Heart"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R78",
              "head_entity_id": "T265",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R79",
              "head_entity_id": "T268",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R80",
              "head_entity_id": "T270",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T269",
              "tail_entity_id": "T267"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R82",
              "head_entity_id": "T271",
              "tail_entity_id": "T267"
            }
          ],
          "sentence_en": "There is limited experience with liraglutide in patients with New York Heart Association (NYHA) class I-II congestive heart failure, and no experience in patients with class III-IV congestive heart failure."
        }
      ],
      "paragraph_en": "There is limited experience with liraglutide in patients with New York Heart Association (NYHA) class I-II congestive heart failure, and no experience in patients with class III-IV congestive heart failure."
    },
    {
      "paragraph_id": "46",
      "paragraph": "·利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·利拉鲁肽不得用于有甲状腺髓样癌(MTC)既往史或家族史患者以及2型多发性内分泌肿瘤综合征患者。",
          "start_idx": 0,
          "end_idx": 48,
          "entities": [
            {
              "entity_id": "T272",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 5,
              "entity_en": "Liraglutide"
            },
            {
              "entity_id": "T273",
              "entity": "甲状腺髓样癌(MTC)",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 21,
              "entity_en": "Medullary thyroid cancer (MTC)"
            },
            {
              "entity_id": "T274",
              "entity": "2型多发性内分泌肿瘤综合征",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 45,
              "entity_en": "Multiple endocrine neoplasia syndrome type 2"
            },
            {
              "entity_id": "T275",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T276",
              "entity": "甲状腺",
              "entity_type": "Anatomy",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "thyroid"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R83",
              "head_entity_id": "T276",
              "tail_entity_id": "T273"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R84",
              "head_entity_id": "T275",
              "tail_entity_id": "T274"
            }
          ],
          "sentence_en": "Liraglutide should not be used in patients with a past or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2."
        }
      ],
      "paragraph_en": "Liraglutide should not be used in patients with a past or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2."
    },
    {
      "paragraph_id": "47",
      "paragraph": "·禁用于对该类产品活性成分或任何其他辅料过敏者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·禁用于对该类产品活性成分或任何其他辅料过敏者。",
          "start_idx": 0,
          "end_idx": 24,
          "entities": [],
          "relations": [],
          "sentence_en": "It is contraindicated for those who are allergic to the active ingredients or any other excipients of this type of product."
        }
      ],
      "paragraph_en": "It is contraindicated for those who are allergic to the active ingredients or any other excipients of this type of product."
    },
    {
      "paragraph_id": "48",
      "paragraph": "(2)额外获益人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)额外获益人群",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "(2) Additional beneficiaries"
        }
      ],
      "paragraph_en": "(2) Additional beneficiaries"
    },
    {
      "paragraph_id": "49",
      "paragraph": "快速建议指南指出，以下人群更加适合使用GLP-1受体激动剂：",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南指出，以下人群更加适合使用GLP-1受体激动剂：",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T277",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 29,
              "entity_en": "GLP-1 receptor agonists"
            }
          ],
          "relations": [],
          "sentence_en": "The rapid advice guide states that the following groups are more suitable for the use of GLP-1 receptor agonists:"
        }
      ],
      "paragraph_en": "The rapid advice guide states that the following groups are more suitable for the use of GLP-1 receptor agonists:"
    },
    {
      "paragraph_id": "50",
      "paragraph": "·由于GLP-1受体激动剂可显著降低患者体重，对于超重肥胖的2型糖尿病患者，建议用于超重/肥胖患者的降糖治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·由于GLP-1受体激动剂可显著降低患者体重，对于超重肥胖的2型糖尿病患者，建议用于超重/肥胖患者的降糖治疗。",
          "start_idx": 0,
          "end_idx": 55,
          "entities": [
            {
              "entity_id": "T278",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 13,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T279",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T280",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T281",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T282",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "obesity"
            },
            {
              "entity_id": "T283",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "overweight"
            },
            {
              "entity_id": "T284",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "obesity"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R85",
              "head_entity_id": "T278",
              "tail_entity_id": "T283"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R86",
              "head_entity_id": "T278",
              "tail_entity_id": "T284"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R87",
              "head_entity_id": "T278",
              "tail_entity_id": "T279"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R88",
              "head_entity_id": "T278",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R89",
              "head_entity_id": "T278",
              "tail_entity_id": "T282"
            }
          ],
          "sentence_en": "Since GLP-1 receptor agonists can significantly reduce the body weight of patients, they are recommended for glucose-lowering treatment in overweight/obese patients with type 2 diabetes."
        }
      ],
      "paragraph_en": "Since GLP-1 receptor agonists can significantly reduce the body weight of patients, they are recommended for glucose-lowering treatment in overweight/obese patients with type 2 diabetes."
    },
    {
      "paragraph_id": "51",
      "paragraph": "·对于伴有非酒精性脂肪肝的2型糖尿病患者，GL-1受体激动剂可降低体质指数(BMl)和转氨酶ALT水平，建议使用GLP-1受体激动剂进行治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "·对于伴有非酒精性脂肪肝的2型糖尿病患者，GL-1受体激动剂可降低体质指数(BMl)和转氨酶ALT水平，建议使用GLP-1受体激动剂进行治疗。",
          "start_idx": 0,
          "end_idx": 71,
          "entities": [
            {
              "entity_id": "T285",
              "entity": "GL-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 30,
              "entity_en": "GL-1 receptor agonists"
            },
            {
              "entity_id": "T286",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 66,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T287",
              "entity": "非酒精性脂肪肝",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 12,
              "entity_en": "Nonalcoholic fatty liver disease"
            },
            {
              "entity_id": "T288",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T289",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T290",
              "entity": "转氨酶ALT",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 49,
              "entity_en": "ALT"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R90",
              "head_entity_id": "T285",
              "tail_entity_id": "T287"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R91",
              "head_entity_id": "T285",
              "tail_entity_id": "T288"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R92",
              "head_entity_id": "T289",
              "tail_entity_id": "T288"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R93",
              "head_entity_id": "T290",
              "tail_entity_id": "T288"
            }
          ],
          "sentence_en": "For patients with type 2 diabetes and non-alcoholic fatty liver disease, GL-1 receptor agonists can reduce body mass index (BMl) and transaminase ALT levels, and GLP-1 receptor agonists are recommended for treatment."
        }
      ],
      "paragraph_en": "For patients with type 2 diabetes and non-alcoholic fatty liver disease, GL-1 receptor agonists can reduce body mass index (BMl) and transaminase ALT levels, and GLP-1 receptor agonists are recommended for treatment."
    },
    {
      "paragraph_id": "52",
      "paragraph": "钠-葡萄糖共转运蛋白2抑制剂：(《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "钠-葡萄糖共转运蛋白2抑制剂：(《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》)",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T291",
              "entity": "钠-葡萄糖共转运蛋白2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 14,
              "entity_en": "Sodium-glucose co-transporter 2 inhibitors"
            },
            {
              "entity_id": "T292",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 39,
              "entity_en": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "Sodium-glucose co-transporter 2 inhibitors: (Chinese expert recommendations on the rational clinical use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors)"
        }
      ],
      "paragraph_en": "Sodium-glucose co-transporter 2 inhibitors: (Chinese expert recommendations on the rational clinical use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors)"
    },
    {
      "paragraph_id": "53",
      "paragraph": "钠-葡萄糖共转运蛋白2抑制剂是一种非常特殊的口服降糖药物，说它特殊是因为，与其他降糖药物都不同的是，它并没有从胰腺、胃肠道等调节血糖的内分泌器官入手，而是作用于葡萄糖的排泄器官一肾脏，通过让更多葡萄糖经肾脏从尿液排出体外来达到降低血糖的效果。大家都知道，只有血糖水平超过肾糖阈时，血中多余的葡萄糖才会从肾脏排泄，这也是血糖需要达到较高水平时尿糖试纸才会有反应的原因。然而，随着研究的深入，人们发现，SGLT-2抑制剂并不仅仅是通过降低肾糖阈来促进葡萄糖经尿排出，它还具有明显的减重效果，并且可降低血压、尿酸水平，减少尿蛋白排泄，降低甘油三酯，同时升高高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)，但不增加LDL/HDL比值。因此，SGLT-2抑制剂这两年也成为临床研究和学术会议的热点。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "钠-葡萄糖共转运蛋白2抑制剂是一种非常特殊的口服降糖药物，说它特殊是因为，与其他降糖药物都不同的是，它并没有从胰腺、胃肠道等调节血糖的内分泌器官入手，而是作用于葡萄糖的排泄器官一肾脏，通过让更多葡萄糖经肾脏从尿液排出体外来达到降低血糖的效果。",
          "start_idx": 0,
          "end_idx": 121,
          "entities": [
            {
              "entity_id": "T293",
              "entity": "钠-葡萄糖共转运蛋白2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 14,
              "entity_en": "Sodium-glucose co-transporter 2 inhibitors"
            },
            {
              "entity_id": "T294",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "oral"
            },
            {
              "entity_id": "T295",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T300",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 115,
              "end_idx": 117,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R94",
              "head_entity_id": "T294",
              "tail_entity_id": "T293"
            }
          ],
          "sentence_en": "Sodium-glucose co-transporter 2 inhibitor is a very special oral hypoglycemic drug. It is special because, unlike other hypoglycemic drugs, it does not start from the endocrine organs that regulate blood sugar, such as the pancreas and gastrointestinal tract, but acts on the glucose excretion organ, the kidney, to achieve the effect of lowering blood sugar by allowing more glucose to be excreted from the body through the kidneys in the urine."
        },
        {
          "sentence_id": "1",
          "sentence": "大家都知道，只有血糖水平超过肾糖阈时，血中多余的葡萄糖才会从肾脏排泄，这也是血糖需要达到较高水平时尿糖试纸才会有反应的原因。",
          "start_idx": 121,
          "end_idx": 183,
          "entities": [
            {
              "entity_id": "T296",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T297",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 38,
              "end_idx": 40,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "As we all know, only when the blood sugar level exceeds the renal glucose threshold will the excess glucose in the blood be excreted from the kidneys. This is why the urine glucose test strip will only react when the blood sugar level reaches a higher level."
        },
        {
          "sentence_id": "2",
          "sentence": "然而，随着研究的深入，人们发现，SGLT-2抑制剂并不仅仅是通过降低肾糖阈来促进葡萄糖经尿排出，它还具有明显的减重效果，并且可降低血压、尿酸水平，减少尿蛋白排泄，降低甘油三酯，同时升高高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)，但不增加LDL/HDL比值。",
          "start_idx": 183,
          "end_idx": 323,
          "entities": [
            {
              "entity_id": "T298",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 25,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T301",
              "entity": "甘油三酯",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 87,
              "entity_en": "Triglycerides"
            },
            {
              "entity_id": "T302",
              "entity": "血压",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 67,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T303",
              "entity": "尿酸",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "Uric acid"
            },
            {
              "entity_id": "T304",
              "entity": "高密度脂蛋白胆固醇(HDL-C)",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 108,
              "entity_en": "High-density lipoprotein cholesterol (HDL-C)"
            },
            {
              "entity_id": "T305",
              "entity": "低密度脂蛋白胆固醇(LDL-C)",
              "entity_type": "Test_items",
              "start_idx": 109,
              "end_idx": 125,
              "entity_en": "Low-density lipoprotein cholesterol (LDL-C)"
            },
            {
              "entity_id": "T306",
              "entity": "LDL/HDL比值",
              "entity_type": "Test_items",
              "start_idx": 130,
              "end_idx": 139,
              "entity_en": "LDL/HDL ratio"
            },
            {
              "entity_id": "T307",
              "entity": "尿蛋白",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "Urine protein"
            }
          ],
          "relations": [],
          "sentence_en": "However, as the research deepened, people found that SGLT-2 inhibitors not only promote the excretion of glucose through urine by lowering the renal glucose threshold, but also have obvious weight loss effects, and can lower blood pressure and uric acid levels, reduce urinary protein excretion, and lower triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), but do not increase the LDL/HDL ratio."
        },
        {
          "sentence_id": "3",
          "sentence": "因此，SGLT-2抑制剂这两年也成为临床研究和学术会议的热点。",
          "start_idx": 323,
          "end_idx": 354,
          "entities": [
            {
              "entity_id": "T299",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 12,
              "entity_en": "SGLT-2 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "Therefore, SGLT-2 inhibitors have become a hot topic in clinical research and academic conferences in the past two years."
        }
      ],
      "paragraph_en": "Sodium-glucose co-transporter 2 inhibitor is a very special oral hypoglycemic drug. It is special because, unlike other hypoglycemic drugs, it does not start from the endocrine organs that regulate blood sugar, such as the pancreas and gastrointestinal tract, but acts on the kidney, the excretion organ of glucose, to achieve the effect of lowering blood sugar by allowing more glucose to be excreted from the body through the kidney in the urine. Everyone knows that only when the blood sugar level exceeds the renal glucose threshold will the excess glucose in the blood be excreted from the kidney. This is also the reason why the urine glucose test strip will only react when the blood sugar level needs to reach a higher level. However, with the deepening of research, people have found that SGLT-2 inhibitors not only promote the excretion of glucose through urine by lowering the renal glucose threshold, but also have a significant weight loss effect, and can lower blood pressure, uric acid levels, reduce urinary protein excretion, and lower triglycerides, while increasing high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), but do not increase the LDL/HDL ratio. Therefore, SGLT-2 inhibitors have also become a hot topic in clinical research and academic conferences in the past two years."
    },
    {
      "paragraph_id": "54",
      "paragraph": "目前，已经有多个SGLT-2抑制剂及其复方制剂在国外上市，并得到越来越多的临床应用。《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》(简称中国建议)发布的时候，我国还没有SGLT-2抑制剂获批上市，但在今年，中国国家食品药品监督管理总局(CFDA)一连批准了两个SGLT-2抑制剂上市，先是在3月份批准达格列净上市，接着在9月份有批准恩格列净上市。相信随着来自中国人群的临床应用证据越来越多，中国建议还将不断完善。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，已经有多个SGLT-2抑制剂及其复方制剂在国外上市，并得到越来越多的临床应用。",
          "start_idx": 0,
          "end_idx": 42,
          "entities": [
            {
              "entity_id": "T308",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 17,
              "entity_en": "SGLT-2 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "At present, several SGLT-2 inhibitors and their combination preparations have been launched overseas and are increasingly being used clinically."
        },
        {
          "sentence_id": "1",
          "sentence": "《钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂临床合理应用中国专家建议》(简称中国建议)发布的时候，我国还没有SGLT-2抑制剂获批上市，但在今年，中国国家食品药品监督管理总局(CFDA)一连批准了两个SGLT-2抑制剂上市，先是在3月份批准达格列净上市，接着在9月份有批准恩格列净上市。",
          "start_idx": 42,
          "end_idx": 186,
          "entities": [
            {
              "entity_id": "T309",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 64,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T310",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 101,
              "end_idx": 110,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T311",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T312",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T313",
              "entity": "钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂",
              "entity_type": "Drug",
              "start_idx": 1,
              "end_idx": 23,
              "entity_en": "Sodium-glucose co-transporter 2 (SGLT-2) inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "When the \"Chinese Expert Recommendations on the Rational Clinical Use of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors\" (referred to as the Chinese Recommendations) was released, no SGLT-2 inhibitors had been approved for marketing in my country. However, this year, the China Food and Drug Administration (CFDA) approved two SGLT-2 inhibitors for marketing in succession, first approving dapagliflozin for marketing in March, and then approving empagliflozin for marketing in September."
        },
        {
          "sentence_id": "2",
          "sentence": "相信随着来自中国人群的临床应用证据越来越多，中国建议还将不断完善。",
          "start_idx": 186,
          "end_idx": 219,
          "entities": [],
          "relations": [],
          "sentence_en": "I believe that as more and more clinical application evidence comes from the Chinese population, China's recommendations will continue to be improved."
        }
      ],
      "paragraph_en": "At present, there are many SGLT-2 inhibitors and their compound preparations on the market abroad and have been increasingly used clinically. When the \"Chinese Expert Recommendations on the Rational Clinical Use of Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors\" (hereinafter referred to as the Chinese Recommendations) was released, there were no SGLT-2 inhibitors approved for marketing in my country. However, this year, the China Food and Drug Administration (CFDA) approved two SGLT-2 inhibitors for marketing, first in March, dapagliflozin, and then in September. It is believed that with more and more clinical application evidence from the Chinese population, the Chinese Recommendations will continue to improve."
    },
    {
      "paragraph_id": "55",
      "paragraph": "适用人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "适用人群",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Target Group"
        }
      ],
      "paragraph_en": "Target Group"
    },
    {
      "paragraph_id": "56",
      "paragraph": "中国建议指出，SGLT-2抑制剂可应用于成人2型糖尿病，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用，也可与其他口服降糖药物及胰岛素联合使用。由于SGLT-2抑制剂的药理作用依赖于一定水平的肾小球滤过率，所以要求患者的估算肾小球滤过率(eGFR)>60或45mI/(min·1.73m2)。CFDA批准的达格列净说明书上所写的适应证为“在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。”目前，SGLT-2抑制剂未被批准用于1型糖尿病；儿童青少年及孕妇和哺乳期妇女中无使用SGLT-2抑制剂的数据，故暂不推荐在此类人群中使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国建议指出，SGLT-2抑制剂可应用于成人2型糖尿病，当饮食和运动不能使血糖得到满意控制或二甲双胍不能耐受时，可单独使用，也可与其他口服降糖药物及胰岛素联合使用。",
          "start_idx": 0,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T314",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 16,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T315",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 50,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T316",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T320",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T324",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 24,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T330",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R95",
              "head_entity_id": "T314",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R96",
              "head_entity_id": "T316",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R97",
              "head_entity_id": "T324",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R98",
              "head_entity_id": "T330",
              "tail_entity_id": "T320"
            }
          ],
          "sentence_en": "China's recommendations point out that SGLT-2 inhibitors can be used in adults with type 2 diabetes. When diet and exercise cannot achieve satisfactory control of blood sugar or metformin is not tolerated, they can be used alone or in combination with other oral hypoglycemic drugs and insulin."
        },
        {
          "sentence_id": "1",
          "sentence": "由于SGLT-2抑制剂的药理作用依赖于一定水平的肾小球滤过率，所以要求患者的估算肾小球滤过率(eGFR)>60或45mI/(min·1.73m2)。",
          "start_idx": 82,
          "end_idx": 156,
          "entities": [
            {
              "entity_id": "T317",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 11,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T327",
              "entity": "肾小球滤过率",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 30,
              "entity_en": "Glomerular filtration rate"
            },
            {
              "entity_id": "T328",
              "entity": "肾小球滤过率(eGFR)",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 52,
              "entity_en": "eGFR"
            },
            {
              "entity_id": "T329",
              "entity": ">60或45mI/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 73,
              "entity_en": ">60 or 45 mI/(min·1.73 m2)"
            }
          ],
          "relations": [],
          "sentence_en": "Since the pharmacological effects of SGLT-2 inhibitors depend on a certain level of glomerular filtration rate, the patient's estimated glomerular filtration rate (eGFR) is required to be >60 or 45mI/(min·1.73m2)."
        },
        {
          "sentence_id": "2",
          "sentence": "CFDA批准的达格列净说明书上所写的适应证为“在饮食和运动基础上，本品可作为单药治疗用于2型糖尿病成人患者改善血糖控制。",
          "start_idx": 156,
          "end_idx": 216,
          "entities": [
            {
              "entity_id": "T321",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T322",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T325",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T331",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 57,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R99",
              "head_entity_id": "T325",
              "tail_entity_id": "T322"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R100",
              "head_entity_id": "T331",
              "tail_entity_id": "T322"
            }
          ],
          "sentence_en": "The indications written in the instructions for dapagliflozin approved by CFDA are \"On the basis of diet and exercise, this product can be used as a monotherapy for adult patients with type 2 diabetes to improve blood sugar control."
        },
        {
          "sentence_id": "3",
          "sentence": "”目前，SGLT-2抑制剂未被批准用于1型糖尿病；儿童青少年及孕妇和哺乳期妇女中无使用SGLT-2抑制剂的数据，故暂不推荐在此类人群中使用。",
          "start_idx": 216,
          "end_idx": 286,
          "entities": [
            {
              "entity_id": "T318",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 13,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T319",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 52,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T323",
              "entity": "1型糖尿病",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Type 1 diabetes"
            },
            {
              "entity_id": "T326",
              "entity": "1型",
              "entity_type": "Class",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "Type 1"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R101",
              "head_entity_id": "T326",
              "tail_entity_id": "T323"
            }
          ],
          "sentence_en": "\"Currently, SGLT-2 inhibitors are not approved for use in type 1 diabetes; there is no data on the use of SGLT-2 inhibitors in children, adolescents, pregnant women, and lactating women, so their use in these populations is not recommended for the time being."
        }
      ],
      "paragraph_en": "China recommends that SGLT-2 inhibitors can be used in adults with type 2 diabetes. When diet and exercise cannot achieve satisfactory blood sugar control or metformin is not tolerated, they can be used alone or in combination with other oral hypoglycemic drugs and insulin. Since the pharmacological effects of SGLT-2 inhibitors depend on a certain level of glomerular filtration rate, the patient's estimated glomerular filtration rate (eGFR) is required to be >60 or 45mI/(min·1.73m2). The indication written on the CFDA-approved dapagliflozin instructions is \"On the basis of diet and exercise, this product can be used as a monotherapy for adult patients with type 2 diabetes to improve blood sugar control.\" At present, SGLT-2 inhibitors are not approved for type 1 diabetes; there is no data on the use of SGLT-2 inhibitors in children, adolescents, pregnant women, and lactating women, so it is not recommended for use in such populations."
    },
    {
      "paragraph_id": "57",
      "paragraph": "临床用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "临床用法",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Clinical Usage"
        }
      ],
      "paragraph_en": "Clinical Usage"
    },
    {
      "paragraph_id": "58",
      "paragraph": "(1)用量",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)用量",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "(1) Dosage"
        }
      ],
      "paragraph_en": "(1) Dosage"
    },
    {
      "paragraph_id": "60",
      "paragraph": "CFDA批准的达格列净剂量规格为5毫克和10毫克两种，说明书给出的用量是，推荐起始剂量为5毫克每日一次，对于需加强血糖控制且耐受5毫克每日一次的患者，可增加至10毫克每日一次。CFDA批准的恩格列净剂量规格只有10毫克一种，所以10毫克起始，最大剂量可能为20毫克(目前尚未得到恩格列净说明书)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "CFDA批准的达格列净剂量规格为5毫克和10毫克两种，说明书给出的用量是，推荐起始剂量为5毫克每日一次，对于需加强血糖控制且耐受5毫克每日一次的患者，可增加至10毫克每日一次。",
          "start_idx": 0,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T332",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T335",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 44,
              "end_idx": 47,
              "entity_en": "5 mg"
            },
            {
              "entity_id": "T336",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 64,
              "end_idx": 67,
              "entity_en": "5 mg"
            },
            {
              "entity_id": "T337",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 79,
              "end_idx": 83,
              "entity_en": "10 mg"
            },
            {
              "entity_id": "T340",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 59,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T341",
              "entity": "每日一次",
              "entity_type": "Frequency",
              "start_idx": 83,
              "end_idx": 87,
              "entity_en": "Once a day"
            },
            {
              "entity_id": "T342",
              "entity": "每日一次",
              "entity_type": "Frequency",
              "start_idx": 47,
              "end_idx": 51,
              "entity_en": "Once a day"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R102",
              "head_entity_id": "T335",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R103",
              "head_entity_id": "T336",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R104",
              "head_entity_id": "T337",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R105",
              "head_entity_id": "T341",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R106",
              "head_entity_id": "T342",
              "tail_entity_id": "T332"
            }
          ],
          "sentence_en": "The CFDA-approved dosage specifications of dapagliflozin are 5 mg and 10 mg. The dosage given in the instructions is that the recommended starting dose is 5 mg once daily. For patients who need to strengthen blood sugar control and can tolerate 5 mg once daily, it can be increased to 10 mg once daily."
        },
        {
          "sentence_id": "1",
          "sentence": "CFDA批准的恩格列净剂量规格只有10毫克一种，所以10毫克起始，最大剂量可能为20毫克(目前尚未得到恩格列净说明书)。",
          "start_idx": 88,
          "end_idx": 148,
          "entities": [
            {
              "entity_id": "T333",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T334",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T338",
              "entity": "20毫克",
              "entity_type": "Amount",
              "start_idx": 40,
              "end_idx": 44,
              "entity_en": "20 mg"
            },
            {
              "entity_id": "T339",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 26,
              "end_idx": 30,
              "entity_en": "10 mg"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R107",
              "head_entity_id": "T339",
              "tail_entity_id": "T333"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R108",
              "head_entity_id": "T338",
              "tail_entity_id": "T333"
            }
          ],
          "sentence_en": "The only dosage of empagliflozin approved by CFDA is 10 mg, so the starting dose is 10 mg and the maximum dose may be 20 mg (the instructions for use of empagliflozin have not yet been obtained)."
        }
      ],
      "paragraph_en": "The dosage specifications of dapagliflozin approved by CFDA are 5 mg and 10 mg. The dosage given in the instructions is that the recommended starting dose is 5 mg once a day. For patients who need to strengthen blood sugar control and can tolerate 5 mg once a day, it can be increased to 10 mg once a day. The dosage specification of empagliflozin approved by CFDA is only 10 mg, so it starts at 10 mg and the maximum dose may be 20 mg (the instructions for empagliflozin have not yet been obtained)."
    },
    {
      "paragraph_id": "61",
      "paragraph": "(2)用法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)用法",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "(2) Usage"
        }
      ],
      "paragraph_en": "(2) Usage"
    },
    {
      "paragraph_id": "62",
      "paragraph": "此类药物均只需晨服一次即可，达格列净和恩格列净餐前或餐后均可服用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "此类药物均只需晨服一次即可，达格列净和恩格列净餐前或餐后均可服用。",
          "start_idx": 0,
          "end_idx": 33,
          "entities": [
            {
              "entity_id": "T343",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T344",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T345",
              "entity": "一次",
              "entity_type": "Frequency",
              "start_idx": 9,
              "end_idx": 11,
              "entity_en": "once"
            }
          ],
          "relations": [
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R109",
              "head_entity_id": "T345",
              "tail_entity_id": "T343"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R110",
              "head_entity_id": "T345",
              "tail_entity_id": "T344"
            }
          ],
          "sentence_en": "These drugs only need to be taken once in the morning, and dapagliflozin and empagliflozin can be taken before or after meals."
        }
      ],
      "paragraph_en": "These drugs only need to be taken once in the morning, and dapagliflozin and empagliflozin can be taken before or after meals."
    },
    {
      "paragraph_id": "63",
      "paragraph": "(3)不良反应处理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)不良反应处理",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": [],
          "sentence_en": "(3) Treatment of adverse reactions"
        }
      ],
      "paragraph_en": "(3) Treatment of adverse reactions"
    },
    {
      "paragraph_id": "64",
      "paragraph": "A.泌尿生殖道感染由于此类药物促进大量葡萄糖从尿液排出，这就增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT-2抑制剂治疗后生殖道感染发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效；女性较男性生殖道感染发生率稍高；有感染疾病史者感染率升高，且感染后需抗感染治疗。女性生殖道感染大部分发生在用药的初始4个月内，最常见的是外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎；男性生殖道感染大部分发生在用药第一年内，最常见的是念珠菌性龟头炎和阴茎包皮炎。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "A.泌尿生殖道感染由于此类药物促进大量葡萄糖从尿液排出，这就增加了泌尿生殖道局部的葡萄糖浓度，导致发生细菌和霉菌感染的机会增加。临床研究数据显示，SGLT-2抑制剂治疗后生殖道感染发生率为4.8%~5.7%，但多为轻到中度感染，常规抗感染治疗有效；女性较男性生殖道感染发生率稍高；有感染疾病史者感染率升高，且感染后需抗感染治疗。",
          "start_idx": 0,
          "end_idx": 164,
          "entities": [
            {
              "entity_id": "T346",
              "entity": "泌尿生殖道感染",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 9,
              "entity_en": "Urogenital tract infection"
            },
            {
              "entity_id": "T347",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 82,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T348",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "Reproductive tract infections"
            },
            {
              "entity_id": "T349",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 111,
              "end_idx": 113,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T350",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 134,
              "entity_en": "Reproductive tract infection"
            },
            {
              "entity_id": "T351",
              "entity": "感染疾病",
              "entity_type": "Disease",
              "start_idx": 141,
              "end_idx": 145,
              "entity_en": "Infectious diseases"
            },
            {
              "entity_id": "T352",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 154,
              "end_idx": 156,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T360",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "Reproductive tract"
            },
            {
              "entity_id": "T361",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "Reproductive tract"
            },
            {
              "entity_id": "T362",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "Reproductive tract"
            },
            {
              "entity_id": "T370",
              "entity": "轻到中度",
              "entity_type": "Level",
              "start_idx": 107,
              "end_idx": 111,
              "entity_en": "Mild to moderate"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R111",
              "head_entity_id": "T360",
              "tail_entity_id": "T346"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R112",
              "head_entity_id": "T361",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R113",
              "head_entity_id": "T362",
              "tail_entity_id": "T350"
            }
          ],
          "sentence_en": "A. Urinary and reproductive tract infection: Since this type of drug promotes the excretion of a large amount of glucose from the urine, this increases the local glucose concentration in the urogenital tract, leading to an increased chance of bacterial and fungal infections. Clinical research data show that the incidence of genital tract infection after SGLT-2 inhibitor treatment is 4.8% to 5.7%, but most of them are mild to moderate infections, and conventional anti-infection treatment is effective; the incidence of genital tract infection in women is slightly higher than that in men; those with a history of infectious diseases have an increased infection rate and require anti-infection treatment after infection."
        },
        {
          "sentence_id": "1",
          "sentence": "女性生殖道感染大部分发生在用药的初始4个月内，最常见的是外阴阴道真菌感染、阴道念珠菌病和外阴阴道炎；男性生殖道感染大部分发生在用药第一年内，最常见的是念珠菌性龟头炎和阴茎包皮炎。",
          "start_idx": 164,
          "end_idx": 253,
          "entities": [
            {
              "entity_id": "T353",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Reproductive tract infection"
            },
            {
              "entity_id": "T354",
              "entity": "外阴阴道真菌感染",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 36,
              "entity_en": "Vulvovaginal yeast infection"
            },
            {
              "entity_id": "T355",
              "entity": "阴道念珠菌病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 43,
              "entity_en": "Vaginal candidiasis"
            },
            {
              "entity_id": "T356",
              "entity": "外阴阴道炎",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49,
              "entity_en": "Vulvovaginitis"
            },
            {
              "entity_id": "T357",
              "entity": "生殖道感染",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57,
              "entity_en": "Reproductive tract infections"
            },
            {
              "entity_id": "T358",
              "entity": "念珠菌性龟头炎",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 82,
              "entity_en": "Candidal balanitis"
            },
            {
              "entity_id": "T359",
              "entity": "阴茎包皮炎",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 88,
              "entity_en": "Phallitis"
            },
            {
              "entity_id": "T363",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "Reproductive tract"
            },
            {
              "entity_id": "T364",
              "entity": "外阴阴道",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 32,
              "entity_en": "Vulvovaginal"
            },
            {
              "entity_id": "T365",
              "entity": "阴道",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 39,
              "entity_en": "vaginal"
            },
            {
              "entity_id": "T366",
              "entity": "外阴阴道",
              "entity_type": "Anatomy",
              "start_idx": 44,
              "end_idx": 48,
              "entity_en": "Vulvovaginal"
            },
            {
              "entity_id": "T367",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 52,
              "end_idx": 55,
              "entity_en": "Reproductive tract"
            },
            {
              "entity_id": "T368",
              "entity": "龟头",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 81,
              "entity_en": "Glans"
            },
            {
              "entity_id": "T369",
              "entity": "阴茎包皮",
              "entity_type": "Anatomy",
              "start_idx": 83,
              "end_idx": 87,
              "entity_en": "Foreskin of penis"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R114",
              "head_entity_id": "T363",
              "tail_entity_id": "T353"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R115",
              "head_entity_id": "T364",
              "tail_entity_id": "T354"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R116",
              "head_entity_id": "T365",
              "tail_entity_id": "T355"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R117",
              "head_entity_id": "T366",
              "tail_entity_id": "T356"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R118",
              "head_entity_id": "T367",
              "tail_entity_id": "T357"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R119",
              "head_entity_id": "T368",
              "tail_entity_id": "T358"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R120",
              "head_entity_id": "T369",
              "tail_entity_id": "T359"
            }
          ],
          "sentence_en": "Most female genital tract infections occur within the first 4 months of medication, the most common of which are vulvovaginal fungal infections, vaginal candidiasis, and vulvovaginitis; most male genital tract infections occur within the first year of medication, the most common of which are candidal balanitis and balanoposthitis."
        }
      ],
      "paragraph_en": "A. Urogenital tract infection Since this type of drug promotes the excretion of a large amount of glucose from the urine, this increases the local glucose concentration in the urogenital tract, leading to an increased chance of bacterial and fungal infections. Clinical research data show that the incidence of genital tract infection after SGLT-2 inhibitor treatment is 4.8%~5.7%, but most of them are mild to moderate infections, and conventional anti-infection treatment is effective; the incidence of genital tract infection in women is slightly higher than that in men; those with a history of infectious diseases have an increased infection rate and require anti-infection treatment after infection. Most female genital tract infections occur within the first 4 months of medication, the most common of which are vulvovaginal fungal infections, vaginal candidiasis, and vulvovaginitis; most male genital tract infections occur within the first year of medication, the most common of which are candidal balanitis and penile prepuce inflammation."
    },
    {
      "paragraph_id": "65",
      "paragraph": "【应对】为避免生殖道和泌尿道感染发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如发生感染并需要抗感染治疗时建议暂时停药，感染治愈后，可继续使用。使用过程中，尤其是第一个月，需要关注是否出现感染的症状和体征，如出现，应及时就医并作相关检查以明确有无感染。患者在使用此类药物过程中，还应当注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "【应对】为避免生殖道和泌尿道感染发生，建议使用前询问病史，半年内反复发生泌尿生殖感染的患者不推荐使用；在使用过程中，如发生感染并需要抗感染治疗时建议暂时停药，感染治愈后，可继续使用。使用过程中，尤其是第一个月，需要关注是否出现感染的症状和体征，如出现，应及时就医并作相关检查以明确有无感染。患者在使用此类药物过程中，还应当注意个人外阴部卫生，适量饮水，保持小便通畅，减少感染发生。",
          "start_idx": 0,
          "end_idx": 190,
          "entities": [
            {
              "entity_id": "T371",
              "entity": "生殖道和泌尿道感染",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 16,
              "entity_en": "Reproductive and urinary tract infections"
            },
            {
              "entity_id": "T372",
              "entity": "泌尿生殖感染",
              "entity_type": "Disease",
              "start_idx": 36,
              "end_idx": 42,
              "entity_en": "Urogenital infections"
            },
            {
              "entity_id": "T373",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T374",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 113,
              "end_idx": 115,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T375",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 144,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T376",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 185,
              "end_idx": 187,
              "entity_en": "Infect"
            },
            {
              "entity_id": "T377",
              "entity": "生殖道",
              "entity_type": "Anatomy",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "Reproductive tract"
            },
            {
              "entity_id": "T378",
              "entity": "泌尿道",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "Urinary tract"
            },
            {
              "entity_id": "T379",
              "entity": "泌尿",
              "entity_type": "Anatomy",
              "start_idx": 36,
              "end_idx": 38,
              "entity_en": "Urinary"
            },
            {
              "entity_id": "T380",
              "entity": "生殖",
              "entity_type": "Anatomy",
              "start_idx": 38,
              "end_idx": 40,
              "entity_en": "Reproduction"
            },
            {
              "entity_id": "T381",
              "entity": "注意个人外阴部卫生",
              "entity_type": "Treatment",
              "start_idx": 161,
              "end_idx": 170,
              "entity_en": "Pay attention to personal genital hygiene"
            },
            {
              "entity_id": "T382",
              "entity": "适量饮水",
              "entity_type": "Treatment",
              "start_idx": 171,
              "end_idx": 175,
              "entity_en": "Drink plenty of water"
            },
            {
              "entity_id": "T383",
              "entity": "保持小便通畅",
              "entity_type": "Treatment",
              "start_idx": 176,
              "end_idx": 182,
              "entity_en": "Keep your bladder open"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R121",
              "head_entity_id": "T377",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R122",
              "head_entity_id": "T378",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R123",
              "head_entity_id": "T379",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R124",
              "head_entity_id": "T380",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R125",
              "head_entity_id": "T381",
              "tail_entity_id": "T376"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R126",
              "head_entity_id": "T382",
              "tail_entity_id": "T376"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R127",
              "head_entity_id": "T383",
              "tail_entity_id": "T376"
            }
          ],
          "sentence_en": "[Response] To avoid genital and urinary tract infections, it is recommended to inquire about medical history before use. It is not recommended for patients with repeated urogenital infections within six months. During use, if an infection occurs and anti-infection treatment is required, it is recommended to temporarily stop the drug. After the infection is cured, it can be continued. During use, especially in the first month, it is necessary to pay attention to whether there are symptoms and signs of infection. If so, seek medical attention in time and undergo relevant examinations to determine whether there is an infection. When using such drugs, patients should also pay attention to personal genital hygiene, drink plenty of water, keep urination unobstructed, and reduce the occurrence of infection."
        }
      ],
      "paragraph_en": "[Response] To avoid genital and urinary tract infections, it is recommended to inquire about medical history before use. It is not recommended for patients with repeated urogenital infections within six months. During use, if an infection occurs and anti-infection treatment is required, it is recommended to temporarily stop the drug. After the infection is cured, it can be continued. During use, especially in the first month, it is necessary to pay attention to whether there are symptoms and signs of infection. If so, seek medical attention in time and undergo relevant examinations to determine whether there is an infection. When using such drugs, patients should also pay attention to personal genital hygiene, drink plenty of water, keep urination unobstructed, and reduce the occurrence of infection."
    },
    {
      "paragraph_id": "66",
      "paragraph": "B.低血糖S GLT-2抑制剂单药治疗不增加低血糖风险；与二甲双胍、DPP-4抑制剂、噻唑烷二酮类等药物联用时，低血糖风险也没有明显增加；与胰岛素或磺脲类药物联用时低血糖风险增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "B.低血糖S GLT-2抑制剂单药治疗不增加低血糖风险；与二甲双胍、DPP-4抑制剂、噻唑烷二酮类等药物联用时，低血糖风险也没有明显增加；与胰岛素或磺脲类药物联用时低血糖风险增加。",
          "start_idx": 0,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T384",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T385",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 42,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T386",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 49,
              "entity_en": "Thiazolidinediones"
            },
            {
              "entity_id": "T387",
              "entity": "S GLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 15,
              "entity_en": "S GLT-2 inhibitors"
            },
            {
              "entity_id": "T388",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T389",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T390",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T391",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T392",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 56,
              "end_idx": 59,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T393",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 82,
              "end_idx": 85,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R128",
              "head_entity_id": "T393",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R129",
              "head_entity_id": "T393",
              "tail_entity_id": "T388"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R130",
              "head_entity_id": "T393",
              "tail_entity_id": "T389"
            }
          ],
          "sentence_en": "B. Hypoglycemia S GLT-2 inhibitor monotherapy does not increase the risk of hypoglycemia; when used in combination with metformin, DPP-4 inhibitors, thiazolidinediones and other drugs, the risk of hypoglycemia is not significantly increased; the risk of hypoglycemia increases when used in combination with insulin or sulfonylureas."
        }
      ],
      "paragraph_en": "B. Hypoglycemia S GLT-2 inhibitor monotherapy does not increase the risk of hypoglycemia; when used in combination with metformin, DPP-4 inhibitors, thiazolidinediones and other drugs, the risk of hypoglycemia is not significantly increased; the risk of hypoglycemia increases when used in combination with insulin or sulfonylureas."
    },
    {
      "paragraph_id": "67",
      "paragraph": "【应对】与胰岛素或磺脲类药物联用时，要注意调整胰岛素或磺脲类药物剂量，加强血糖监测，避免低血糖发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "【应对】与胰岛素或磺脲类药物联用时，要注意调整胰岛素或磺脲类药物剂量，加强血糖监测，避免低血糖发生。",
          "start_idx": 0,
          "end_idx": 50,
          "entities": [
            {
              "entity_id": "T394",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T395",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T396",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T397",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T398",
              "entity": "血糖监测",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 41,
              "entity_en": "Blood glucose monitoring"
            },
            {
              "entity_id": "T399",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 44,
              "end_idx": 47,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R131",
              "head_entity_id": "T399",
              "tail_entity_id": "T394"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R132",
              "head_entity_id": "T399",
              "tail_entity_id": "T395"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R133",
              "head_entity_id": "T399",
              "tail_entity_id": "T396"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R134",
              "head_entity_id": "T399",
              "tail_entity_id": "T397"
            }
          ],
          "sentence_en": "[Response] When used in combination with insulin or sulfonylureas, pay attention to adjusting the dosage of insulin or sulfonylureas, strengthen blood sugar monitoring, and avoid hypoglycemia."
        }
      ],
      "paragraph_en": "[Response] When used in combination with insulin or sulfonylureas, pay attention to adjusting the dosage of insulin or sulfonylureas, strengthen blood sugar monitoring, and avoid hypoglycemia."
    },
    {
      "paragraph_id": "68",
      "paragraph": "C.DKA SGLT-2抑制剂在上市前研究和上市后应用过程中，都有过糖尿病酮症酸中毒(DKA)及酮症的病例报告，但非常少见。发生者大多存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理应激等诱因，部分联用胰岛素的患者胰岛素减量过快。使用此类药物发生DKA及酮症的患者症状不典型，血糖通常不超过13.9毫摩尔/升，被称为“血糖不高的DKA”，往往不易被诊断。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "C.DKA SGLT-2抑制剂在上市前研究和上市后应用过程中，都有过糖尿病酮症酸中毒(DKA)及酮症的病例报告，但非常少见。发生者大多存在手术、过度运动、心肌梗死、卒中、严重感染、长时间禁食或极低碳水化合物摄入量和其他生理及病理应激等诱因，部分联用胰岛素的患者胰岛素减量过快。使用此类药物发生DKA及酮症的患者症状不典型，血糖通常不超过13.9毫摩尔/升，被称为“血糖不高的DKA”，往往不易被诊断。",
          "start_idx": 0,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T400",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 15,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T401",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T402",
              "entity": "糖尿病酮症酸中毒(DKA)",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 47,
              "entity_en": "Diabetic ketoacidosis (DKA)"
            },
            {
              "entity_id": "T403",
              "entity": "酮症",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 50,
              "entity_en": "Ketosis"
            },
            {
              "entity_id": "T404",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 146,
              "end_idx": 149,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T405",
              "entity": "酮症",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 152,
              "entity_en": "Ketosis"
            },
            {
              "entity_id": "T406",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 190,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T407",
              "entity": "手术",
              "entity_type": "Reason",
              "start_idx": 69,
              "end_idx": 71,
              "entity_en": "Operation"
            },
            {
              "entity_id": "T408",
              "entity": "过度运动",
              "entity_type": "Reason",
              "start_idx": 72,
              "end_idx": 76,
              "entity_en": "Excessive exercise"
            },
            {
              "entity_id": "T409",
              "entity": "心肌梗死",
              "entity_type": "Reason",
              "start_idx": 77,
              "end_idx": 81,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T410",
              "entity": "卒中",
              "entity_type": "Reason",
              "start_idx": 82,
              "end_idx": 84,
              "entity_en": "Stroke"
            },
            {
              "entity_id": "T411",
              "entity": "严重感染",
              "entity_type": "Reason",
              "start_idx": 85,
              "end_idx": 89,
              "entity_en": "Severe infection"
            },
            {
              "entity_id": "T412",
              "entity": "长时间禁食",
              "entity_type": "Reason",
              "start_idx": 90,
              "end_idx": 95,
              "entity_en": "Prolonged fasting"
            },
            {
              "entity_id": "T413",
              "entity": "极低碳水化合物摄入量",
              "entity_type": "Reason",
              "start_idx": 96,
              "end_idx": 106,
              "entity_en": "Very low carbohydrate intake"
            },
            {
              "entity_id": "T414",
              "entity": "其他生理及病理应激",
              "entity_type": "Reason",
              "start_idx": 107,
              "end_idx": 116,
              "entity_en": "Other physiological and pathological stress"
            },
            {
              "entity_id": "T415",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 127,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T416",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 133,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T417",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 161,
              "end_idx": 163,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T418",
              "entity": "不超过13.9毫摩尔/升",
              "entity_type": "Test_Value",
              "start_idx": 165,
              "end_idx": 177,
              "entity_en": "Not more than 13.9 mmol/L"
            },
            {
              "entity_id": "T419",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 182,
              "end_idx": 184,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T420",
              "entity": "不高",
              "entity_type": "Test_Value",
              "start_idx": 184,
              "end_idx": 186,
              "entity_en": "Not high"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R135",
              "head_entity_id": "T419",
              "tail_entity_id": "T406"
            }
          ],
          "sentence_en": "C.DKA There have been case reports of diabetic ketoacidosis (DKA) and ketosis during the pre-marketing research and post-marketing application of SGLT-2 inhibitors, but they are very rare. Most of the cases have causes such as surgery, excessive exercise, myocardial infarction, stroke, severe infection, long-term fasting or very low carbohydrate intake and other physiological and pathological stresses. Some patients who use insulin in combination have too fast insulin reduction. Patients who use this type of drug and develop DKA and ketosis have atypical symptoms, and their blood sugar usually does not exceed 13.9 mmol/L. This is called \"DKA without high blood sugar\" and is often difficult to diagnose."
        }
      ],
      "paragraph_en": "C.DKA There have been case reports of diabetic ketoacidosis (DKA) and ketosis during the pre-marketing research and post-marketing application of SGLT-2 inhibitors, but they are very rare. Most of the cases have causes such as surgery, excessive exercise, myocardial infarction, stroke, severe infection, long-term fasting or very low carbohydrate intake and other physiological and pathological stresses. Some patients who use insulin in combination have too fast insulin reduction. Patients who use this type of drug and develop DKA and ketosis have atypical symptoms, and their blood sugar usually does not exceed 13.9 mmol/L. This is called \"DKA without high blood sugar\" and is often difficult to diagnose."
    },
    {
      "paragraph_id": "69",
      "paragraph": "【应对】用药期间，如出现和DKA相关的症状，如腹痛、恶心、呕吐、乏力、呼吸困难，需要考虑是否出现DKA并检测血酮和动脉血酸碱度以明确诊断。明确诊断为DKA者，应立即停用SGLT-2抑制剂，并按照传统DKA治疗程序进行治疗。为减少用药期间发生DKA的风险，建议在择期手术、剧烈体力活动(如马拉松)前24小时停用SGLT-2抑制剂，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT-2抑制剂，采用其他合适降糖措施；口服SGLT2抑制剂期间避免过多饮酒及极低碳水化合物饮食。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "【应对】用药期间，如出现和DKA相关的症状，如腹痛、恶心、呕吐、乏力、呼吸困难，需要考虑是否出现DKA并检测血酮和动脉血酸碱度以明确诊断。明确诊断为DKA者，应立即停用SGLT-2抑制剂，并按照传统DKA治疗程序进行治疗。为减少用药期间发生DKA的风险，建议在择期手术、剧烈体力活动(如马拉松)前24小时停用SGLT-2抑制剂，同时注意停药后的后续效应；避免停用胰岛素或过度减量；对于紧急手术或大的应激状态，需立即停用SGLT-2抑制剂，采用其他合适降糖措施；口服SGLT2抑制剂期间避免过多饮酒及极低碳水化合物饮食。",
          "start_idx": 0,
          "end_idx": 259,
          "entities": [
            {
              "entity_id": "T421",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 16,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T422",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T423",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 77,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T424",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 102,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T425",
              "entity": "DKA",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 123,
              "entity_en": "DKA"
            },
            {
              "entity_id": "T426",
              "entity": "腹痛",
              "entity_type": "Symptom",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "stomach ache"
            },
            {
              "entity_id": "T427",
              "entity": "恶心",
              "entity_type": "Symptom",
              "start_idx": 26,
              "end_idx": 28,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T428",
              "entity": "呕吐",
              "entity_type": "Symptom",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "Vomit"
            },
            {
              "entity_id": "T429",
              "entity": "乏力",
              "entity_type": "Symptom",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "Fatigue"
            },
            {
              "entity_id": "T430",
              "entity": "呼吸困难",
              "entity_type": "Symptom",
              "start_idx": 35,
              "end_idx": 39,
              "entity_en": "trouble breathing"
            },
            {
              "entity_id": "T431",
              "entity": "血酮",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "Blood ketones"
            },
            {
              "entity_id": "T432",
              "entity": "动脉血酸碱度",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 63,
              "entity_en": "Arterial pH"
            },
            {
              "entity_id": "T433",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 84,
              "end_idx": 93,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T434",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 154,
              "end_idx": 163,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T435",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 181,
              "end_idx": 184,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T436",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 209,
              "end_idx": 218,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T437",
              "entity": "SGLT2抑制剂",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 240,
              "entity_en": "SGLT2 inhibitors"
            },
            {
              "entity_id": "T438",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 230,
              "end_idx": 232,
              "entity_en": "oral"
            }
          ],
          "relations": [
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R136",
              "head_entity_id": "T426",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R137",
              "head_entity_id": "T427",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R138",
              "head_entity_id": "T428",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R139",
              "head_entity_id": "T429",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Symptom_Disease",
              "relation_id": "R140",
              "head_entity_id": "T430",
              "tail_entity_id": "T421"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R141",
              "head_entity_id": "T431",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R142",
              "head_entity_id": "T432",
              "tail_entity_id": "T422"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R143",
              "head_entity_id": "T438",
              "tail_entity_id": "T437"
            }
          ],
          "sentence_en": "[Response] During medication, if symptoms related to DKA occur, such as abdominal pain, nausea, vomiting, fatigue, and dyspnea, it is necessary to consider whether DKA has occurred and test blood ketones and arterial blood pH to confirm the diagnosis. For those diagnosed with DKA, SGLT-2 inhibitors should be discontinued immediately and treated according to traditional DKA treatment procedures. To reduce the risk of DKA during medication, it is recommended to discontinue SGLT-2 inhibitors 24 hours before elective surgery or strenuous physical activity (such as marathon), and pay attention to the subsequent effects after discontinuation of the drug; avoid discontinuing insulin or excessive dose reduction; for emergency surgery or severe stress, SGLT-2 inhibitors must be discontinued immediately and other appropriate blood sugar-lowering measures should be adopted; avoid excessive drinking and very low-carbohydrate diets during oral SGLT2 inhibitors."
        }
      ],
      "paragraph_en": "[Response] During medication, if symptoms related to DKA occur, such as abdominal pain, nausea, vomiting, fatigue, and dyspnea, it is necessary to consider whether DKA has occurred and test blood ketones and arterial blood pH to confirm the diagnosis. For those diagnosed with DKA, SGLT-2 inhibitors should be discontinued immediately and treated according to traditional DKA treatment procedures. To reduce the risk of DKA during medication, it is recommended to discontinue SGLT-2 inhibitors 24 hours before elective surgery or strenuous physical activity (such as marathon), and pay attention to the subsequent effects after discontinuation of the drug; avoid discontinuing insulin or excessive dose reduction; for emergency surgery or severe stress, SGLT-2 inhibitors must be discontinued immediately and other appropriate blood sugar-lowering measures should be adopted; avoid excessive drinking and very low-carbohydrate diets during oral SGLT2 inhibitors."
    },
    {
      "paragraph_id": "70",
      "paragraph": "特殊情况",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "特殊情况",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": [],
          "sentence_en": "Special circumstances"
        }
      ],
      "paragraph_en": "Special circumstances"
    },
    {
      "paragraph_id": "71",
      "paragraph": "(1)老年",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)老年",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "(1) Old age"
        }
      ],
      "paragraph_en": "(1) Old age"
    },
    {
      "paragraph_id": "72",
      "paragraph": "老年患者在原有治疗方案疗效不佳时加用SGLT-2抑制剂，可有效降低血糖、减轻体重和降低血压，且耐受性良好。不过，老年患者需监测肾功能，肾功能正常或轻度不全时可使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "老年患者在原有治疗方案疗效不佳时加用SGLT-2抑制剂，可有效降低血糖、减轻体重和降低血压，且耐受性良好。",
          "start_idx": 0,
          "end_idx": 53,
          "entities": [
            {
              "entity_id": "T439",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 27,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T441",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T442",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 43,
              "end_idx": 45,
              "entity_en": "blood pressure"
            }
          ],
          "relations": [],
          "sentence_en": "When the original treatment regimen is ineffective for elderly patients, adding SGLT-2 inhibitors can effectively lower blood sugar, reduce weight and lower blood pressure, and is well tolerated."
        },
        {
          "sentence_id": "1",
          "sentence": "不过，老年患者需监测肾功能，肾功能正常或轻度不全时可使用。",
          "start_idx": 53,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T440",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 8,
              "end_idx": 13,
              "entity_en": "Monitoring renal function"
            },
            {
              "entity_id": "T443",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "Mild"
            }
          ],
          "relations": [],
          "sentence_en": "However, renal function of elderly patients needs to be monitored, and it can be used when renal function is normal or mildly impaired."
        }
      ],
      "paragraph_en": "When the original treatment regimen is ineffective for elderly patients, adding SGLT-2 inhibitors can effectively lower blood sugar, reduce weight and lower blood pressure, and is well tolerated. However, elderly patients need to monitor their renal function and can use them when their renal function is normal or mildly insufficiency."
    },
    {
      "paragraph_id": "74",
      "paragraph": "SGLT-2抑制剂在中度肾功能不全患者可减量使用，起始治疗前需检测肾功能，根据肾功能确认是否可以起始，治疗中每年至少监测一次肾功能，如同时予以影响肾功能的药物，起始前也需监测肾功能，当肾功能逐渐下降并趋向于中度肾功能不全时，则需每年监测2~4次肾功能。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂在中度肾功能不全患者可减量使用，起始治疗前需检测肾功能，根据肾功能确认是否可以起始，治疗中每年至少监测一次肾功能，如同时予以影响肾功能的药物，起始前也需监测肾功能，当肾功能逐渐下降并趋向于中度肾功能不全时，则需每年监测2~4次肾功能。",
          "start_idx": 0,
          "end_idx": 126,
          "entities": [
            {
              "entity_id": "T444",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T445",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T446",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 13,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T447",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 105,
              "end_idx": 110,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T448",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T449",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T450",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 103,
              "end_idx": 105,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T451",
              "entity": "检测肾功能",
              "entity_type": "Test",
              "start_idx": 31,
              "end_idx": 36,
              "entity_en": "Testing kidney function"
            },
            {
              "entity_id": "T452",
              "entity": "监测一次肾功能",
              "entity_type": "Test",
              "start_idx": 58,
              "end_idx": 65,
              "entity_en": "Monitor renal function once"
            },
            {
              "entity_id": "T453",
              "entity": "监测肾功能",
              "entity_type": "Test",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "Monitoring renal function"
            },
            {
              "entity_id": "T454",
              "entity": "监测2~4次肾功能",
              "entity_type": "Test",
              "start_idx": 116,
              "end_idx": 125,
              "entity_en": "Monitor renal function 2 to 4 times"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T444",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R145",
              "head_entity_id": "T446",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R146",
              "head_entity_id": "T451",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R147",
              "head_entity_id": "T448",
              "tail_entity_id": "T447"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R148",
              "head_entity_id": "T454",
              "tail_entity_id": "T447"
            }
          ],
          "sentence_en": "SGLT-2 inhibitors can be used in reduced doses in patients with moderate renal impairment. Renal function needs to be tested before starting treatment, and whether treatment can be started is determined based on renal function. Renal function should be monitored at least once a year during treatment. If drugs that affect renal function are given at the same time, renal function also needs to be monitored before starting treatment. When renal function gradually declines and tends towards moderate renal impairment, renal function needs to be monitored 2 to 4 times a year."
        }
      ],
      "paragraph_en": "SGLT-2 inhibitors can be used in reduced doses in patients with moderate renal impairment. Renal function needs to be tested before starting treatment, and whether treatment can be started is determined based on renal function. Renal function should be monitored at least once a year during treatment. If drugs that affect renal function are given at the same time, renal function also needs to be monitored before starting treatment. When renal function gradually declines and tends towards moderate renal impairment, renal function needs to be monitored 2 to 4 times a year."
    },
    {
      "paragraph_id": "75",
      "paragraph": "SGLT-2抑制剂在轻中度肝功能不全时也可使用。由于在重度肝功能不全的2型糖尿病患者中使用数据有限。欧美国家的药物说明书中均不推荐用于重度肝功能不全患者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂在轻中度肝功能不全时也可使用。由于在重度肝功能不全的2型糖尿病患者中使用数据有限。欧美国家的药物说明书中均不推荐用于重度肝功能不全患者。",
          "start_idx": 0,
          "end_idx": 77,
          "entities": [
            {
              "entity_id": "T455",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T456",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 13,
              "end_idx": 18,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T457",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 13,
              "end_idx": 14,
              "entity_en": "liver"
            },
            {
              "entity_id": "T458",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T459",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T460",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 74,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T461",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 29,
              "end_idx": 30,
              "entity_en": "liver"
            },
            {
              "entity_id": "T462",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 69,
              "end_idx": 70,
              "entity_en": "liver"
            },
            {
              "entity_id": "T463",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 35,
              "end_idx": 37,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T464",
              "entity": "轻中度",
              "entity_type": "Level",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Mild to moderate"
            },
            {
              "entity_id": "T465",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 27,
              "end_idx": 29,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T466",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "Severe"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R149",
              "head_entity_id": "T455",
              "tail_entity_id": "T456"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R150",
              "head_entity_id": "T457",
              "tail_entity_id": "T456"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R151",
              "head_entity_id": "T461",
              "tail_entity_id": "T458"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R152",
              "head_entity_id": "T463",
              "tail_entity_id": "T459"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R153",
              "head_entity_id": "T462",
              "tail_entity_id": "T460"
            }
          ],
          "sentence_en": "SGLT-2 inhibitors can also be used in patients with mild to moderate hepatic insufficiency. However, there is limited data on their use in patients with type 2 diabetes and severe hepatic insufficiency. Drug instructions in European and American countries do not recommend their use in patients with severe hepatic insufficiency."
        }
      ],
      "paragraph_en": "SGLT-2 inhibitors can also be used in patients with mild to moderate hepatic insufficiency. However, there is limited data on their use in patients with type 2 diabetes and severe hepatic insufficiency. Drug instructions in European and American countries do not recommend their use in patients with severe hepatic insufficiency."
    },
    {
      "paragraph_id": "76",
      "paragraph": "(3)心血管疾病",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)心血管疾病",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [
            {
              "entity_id": "T467",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 8,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T468",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 6,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R154",
              "head_entity_id": "T468",
              "tail_entity_id": "T467"
            }
          ],
          "sentence_en": "(3) Cardiovascular disease"
        }
      ],
      "paragraph_en": "(3) Cardiovascular disease"
    },
    {
      "paragraph_id": "77",
      "paragraph": "SGLT-2抑制剂除有效降糖外。还具有减重、降压、降尿酸、减少蛋白尿等与心血管疾病相关危险因素的作用，目前也有一些研究证实此类药物确实能够降低心血管事件风险。不过，由于此类药物刚刚进入中国，我们还需要更多的临床数据去了解它们。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "SGLT-2抑制剂除有效降糖外。",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [
            {
              "entity_id": "T469",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Disease",
              "start_idx": 0,
              "end_idx": 9,
              "entity_en": "SGLT-2 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "In addition to being effective in lowering blood sugar, SGLT-2 inhibitors"
        },
        {
          "sentence_id": "1",
          "sentence": "还具有减重、降压、降尿酸、减少蛋白尿等与心血管疾病相关危险因素的作用，目前也有一些研究证实此类药物确实能够降低心血管事件风险。",
          "start_idx": 16,
          "end_idx": 79,
          "entities": [
            {
              "entity_id": "T470",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T471",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 23,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T472",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 60,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T473",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 55,
              "end_idx": 58,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R155",
              "head_entity_id": "T471",
              "tail_entity_id": "T470"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R156",
              "head_entity_id": "T473",
              "tail_entity_id": "T472"
            }
          ],
          "sentence_en": "It also has the effects of reducing weight, lowering blood pressure, lowering uric acid, reducing proteinuria and other risk factors related to cardiovascular diseases. Some studies have also confirmed that such drugs can indeed reduce the risk of cardiovascular events."
        },
        {
          "sentence_id": "2",
          "sentence": "不过，由于此类药物刚刚进入中国，我们还需要更多的临床数据去了解它们。",
          "start_idx": 79,
          "end_idx": 113,
          "entities": [],
          "relations": [],
          "sentence_en": "However, since these drugs have just entered China, we still need more clinical data to understand them."
        }
      ],
      "paragraph_en": "In addition to effectively lowering blood sugar, SGLT-2 inhibitors also have the effects of reducing weight, blood pressure, uric acid, and proteinuria, which are related to cardiovascular disease risk factors. At present, some studies have confirmed that such drugs can indeed reduce the risk of cardiovascular events. However, since such drugs have just entered China, we still need more clinical data to understand them."
    },
    {
      "paragraph_id": "78",
      "paragraph": "(4)其他",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)其他",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": [],
          "sentence_en": "(4) Others"
        }
      ],
      "paragraph_en": "(4) Others"
    },
    {
      "paragraph_id": "79",
      "paragraph": "目前，临床研究数据尚未证实此类药物与膀胱癌风险存在因果关系，上市后至今尚无相关肿瘤病例报告；FDA和EMA根据不良事件报告系统的数据，已加强提醒在使用SGLT-2抑制剂过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净、坎格列净)，但它们之间是否存在因果关系仍需要进一步研究。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "目前，临床研究数据尚未证实此类药物与膀胱癌风险存在因果关系，上市后至今尚无相关肿瘤病例报告；FDA和EMA根据不良事件报告系统的数据，已加强提醒在使用SGLT-2抑制剂过程中，注意骨折风险(坎格列净)、足趾截肢风险(坎格列净)及急性肾损伤风险(达格列净、坎格列净)，但它们之间是否存在因果关系仍需要进一步研究。",
          "start_idx": 0,
          "end_idx": 155,
          "entities": [
            {
              "entity_id": "T474",
              "entity": "膀胱癌",
              "entity_type": "Disease",
              "start_idx": 18,
              "end_idx": 21,
              "entity_en": "Bladder cancer"
            },
            {
              "entity_id": "T475",
              "entity": "膀胱",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "bladder"
            },
            {
              "entity_id": "T476",
              "entity": "肿瘤",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "Tumor"
            },
            {
              "entity_id": "T477",
              "entity": "SGLT-2抑制剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 84,
              "entity_en": "SGLT-2 inhibitors"
            },
            {
              "entity_id": "T478",
              "entity": "骨折",
              "entity_type": "Disease",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "fracture"
            },
            {
              "entity_id": "T479",
              "entity": "足趾截肢",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 105,
              "entity_en": "Toe amputation"
            },
            {
              "entity_id": "T480",
              "entity": "足趾",
              "entity_type": "Anatomy",
              "start_idx": 101,
              "end_idx": 103,
              "entity_en": "Toes"
            },
            {
              "entity_id": "T481",
              "entity": "急性肾损伤",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 119,
              "entity_en": "Acute kidney injury"
            },
            {
              "entity_id": "T482",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 116,
              "end_idx": 117,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T483",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 122,
              "end_idx": 126,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T484",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Canagliflozin"
            },
            {
              "entity_id": "T485",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "Canagliflozin"
            },
            {
              "entity_id": "T486",
              "entity": "坎格列净",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112,
              "entity_en": "Canagliflozin"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R157",
              "head_entity_id": "T475",
              "tail_entity_id": "T474"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R158",
              "head_entity_id": "T477",
              "tail_entity_id": "T476"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R159",
              "head_entity_id": "T480",
              "tail_entity_id": "T479"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R160",
              "head_entity_id": "T482",
              "tail_entity_id": "T481"
            }
          ],
          "sentence_en": "At present, clinical research data have not confirmed a causal relationship between this type of drug and the risk of bladder cancer, and there have been no related tumor case reports since its launch. Based on data from the adverse event reporting system, the FDA and EMA have strengthened reminders to pay attention to the risks of fractures (canagliflozin), toe amputation (canagliflozin), and acute kidney injury (dapagliflozin, canagliflozin) during the use of SGLT-2 inhibitors, but whether there is a causal relationship between them still needs further study."
        }
      ],
      "paragraph_en": "At present, clinical research data have not confirmed a causal relationship between this type of drug and the risk of bladder cancer, and there have been no related tumor case reports since its launch. Based on data from the adverse event reporting system, the FDA and EMA have strengthened reminders to pay attention to the risks of fractures (canagliflozin), toe amputation (canagliflozin), and acute kidney injury (dapagliflozin, canagliflozin) during the use of SGLT-2 inhibitors, but whether there is a causal relationship between them still needs further study."
    },
    {
      "paragraph_id": "73",
      "paragraph": "(2)肝肾功能不全",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)肝肾功能不全",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [
            {
              "entity_id": "T487",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T488",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 3,
              "end_idx": 4,
              "entity_en": "liver"
            },
            {
              "entity_id": "T489",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5,
              "entity_en": "kidney"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R161",
              "head_entity_id": "T489",
              "tail_entity_id": "T487"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R162",
              "head_entity_id": "T488",
              "tail_entity_id": "T487"
            }
          ],
          "sentence_en": "(2) Liver and kidney dysfunction"
        }
      ],
      "paragraph_en": "(2) Liver and kidney dysfunction"
    },
    {
      "paragraph_id": "59",
      "paragraph": "由于中国建议发布时，此类药物尚未在国内上市，所以仅介绍了国外的使用情况，美国药品食品监督管理局(FDA)批准达格列净和恩格列净的起始剂量分别为5毫克和10毫克，根据血糖控制的需求和是否耐受可调整至最大剂量10毫克和25毫克，每日一次口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10毫克，对于重度肝功能不全的患者可从5毫克起始。美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT一2抑制剂可单独使用及与其他降糖药物联合使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "由于中国建议发布时，此类药物尚未在国内上市，所以仅介绍了国外的使用情况，美国药品食品监督管理局(FDA)批准达格列净和恩格列净的起始剂量分别为5毫克和10毫克，根据血糖控制的需求和是否耐受可调整至最大剂量10毫克和25毫克，每日一次口服。与FDA不同的是，欧洲药物机构(EMA)推荐达格列净的起始剂量为10毫克，对于重度肝功能不全的患者可从5毫克起始。",
          "start_idx": 0,
          "end_idx": 176,
          "entities": [
            {
              "entity_id": "T490",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T491",
              "entity": "恩格列净",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Empagliflozin"
            },
            {
              "entity_id": "T492",
              "entity": "达格列净",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 145,
              "entity_en": "Dapagliflozin"
            },
            {
              "entity_id": "T494",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 71,
              "end_idx": 74,
              "entity_en": "5 mg"
            },
            {
              "entity_id": "T495",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "10 mg"
            },
            {
              "entity_id": "T496",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "10 mg"
            },
            {
              "entity_id": "T497",
              "entity": "25毫克",
              "entity_type": "Amount",
              "start_idx": 107,
              "end_idx": 111,
              "entity_en": "25 mg"
            },
            {
              "entity_id": "T498",
              "entity": "10毫克",
              "entity_type": "Amount",
              "start_idx": 151,
              "end_idx": 155,
              "entity_en": "10 mg"
            },
            {
              "entity_id": "T499",
              "entity": "5毫克",
              "entity_type": "Amount",
              "start_idx": 170,
              "end_idx": 173,
              "entity_en": "5 mg"
            },
            {
              "entity_id": "T500",
              "entity": "每日一次",
              "entity_type": "Frequency",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Once a day"
            },
            {
              "entity_id": "T501",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 116,
              "end_idx": 118,
              "entity_en": "oral"
            },
            {
              "entity_id": "T502",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 160,
              "end_idx": 165,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T503",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 160,
              "end_idx": 161,
              "entity_en": "liver"
            },
            {
              "entity_id": "T504",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 158,
              "end_idx": 160,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T505",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 84,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R163",
              "head_entity_id": "T494",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R164",
              "head_entity_id": "T496",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R165",
              "head_entity_id": "T500",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R166",
              "head_entity_id": "T501",
              "tail_entity_id": "T490"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R167",
              "head_entity_id": "T495",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R168",
              "head_entity_id": "T497",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R169",
              "head_entity_id": "T500",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R170",
              "head_entity_id": "T501",
              "tail_entity_id": "T491"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R171",
              "head_entity_id": "T498",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R172",
              "head_entity_id": "T499",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R173",
              "head_entity_id": "T492",
              "tail_entity_id": "T502"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R174",
              "head_entity_id": "T503",
              "tail_entity_id": "T502"
            }
          ],
          "sentence_en": "Since such drugs were not available in China when the Chinese recommendations were issued, only the overseas usage was introduced. The US Food and Drug Administration (FDA) approved the starting doses of dapagliflozin and empagliflozin to be 5 mg and 10 mg respectively, which can be adjusted to the maximum dose of 10 mg and 25 mg according to the needs of blood sugar control and tolerance, taken orally once a day. Unlike the FDA, the European Medicines Agency (EMA) recommends a starting dose of 10 mg for dapagliflozin, and for patients with severe liver dysfunction, it can start with 5 mg."
        },
        {
          "sentence_id": "1",
          "sentence": "美国临床内分泌医师协会(AACE)、美国糖尿病学会和欧洲糖尿病学会(ADA/EASD)指南推荐SGLT一2抑制剂可单独使用及与其他降糖药物联合使用。",
          "start_idx": 176,
          "end_idx": 250,
          "entities": [
            {
              "entity_id": "T493",
              "entity": "SGLT一2抑制剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 56,
              "entity_en": "SGLT-2 inhibitors"
            }
          ],
          "relations": [],
          "sentence_en": "Guidelines from the American Association of Clinical Endocrinologists (AACE), the American Diabetes Association, and the European Association for the Study of Diabetes (ADA/EASD) recommend that SGLT-2 inhibitors can be used alone or in combination with other glucose-lowering drugs."
        }
      ],
      "paragraph_en": "Since such drugs were not available in China when the Chinese recommendations were issued, only their use abroad was introduced. The U.S. Food and Drug Administration (FDA) approved the starting doses of dapagliflozin and empagliflozin to be 5 mg and 10 mg, respectively, which can be adjusted to a maximum dose of 10 mg and 25 mg, orally once a day, depending on the need for blood sugar control and tolerance. Unlike the FDA, the European Medicines Agency (EMA) recommends a starting dose of 10 mg for dapagliflozin, and 5 mg can be used as a starting dose for patients with severe liver dysfunction. The guidelines of the American Association of Clinical Endocrinologists (AACE), the American Association of Diabetes, and the European Association of Diabetes (ADA/EASD) recommend that SGLT-2 inhibitors can be used alone or in combination with other glucose-lowering drugs."
    },
    {
      "paragraph_id": "19",
      "paragraph": "快速建议指南推荐DPP-4抑制剂联合基础胰岛用于2型糖尿病患者的降糖治疗，指出当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，添加DPP-4抑制剂进行联合治疗，并根据糖化血红白水平，调整胰岛素的剂量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "快速建议指南推荐DPP-4抑制剂联合基础胰岛用于2型糖尿病患者的降糖治疗，指出当使用基础胰岛素进行治疗，糖化血红蛋白水平仍控制不佳时，添加DPP-4抑制剂进行联合治疗，并根据糖化血红白水平，调整胰岛素的剂量。",
          "start_idx": 0,
          "end_idx": 104,
          "entities": [
            {
              "entity_id": "T506",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T507",
              "entity": "基础胰岛",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22,
              "entity_en": "Basic islets"
            },
            {
              "entity_id": "T508",
              "entity": "基础胰岛素",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 47,
              "entity_en": "Basal insulin"
            },
            {
              "entity_id": "T509",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 77,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T510",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 100,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T511",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 29,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T512",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T513",
              "entity": "糖化血红蛋白",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 58,
              "entity_en": "Glycated hemoglobin"
            },
            {
              "entity_id": "T514",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T515",
              "entity": "糖化血红白",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 92,
              "entity_en": "Glycated hemoglobin"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R175",
              "head_entity_id": "T506",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R176",
              "head_entity_id": "T507",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R177",
              "head_entity_id": "T512",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R178",
              "head_entity_id": "T513",
              "tail_entity_id": "T511"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R179",
              "head_entity_id": "T515",
              "tail_entity_id": "T511"
            }
          ],
          "sentence_en": "The rapid advice guideline recommends DPP-4 inhibitors combined with basal insulin for glucose-lowering treatment in patients with type 2 diabetes, pointing out that when basal insulin is used for treatment and the glycated hemoglobin level is still poorly controlled, DPP-4 inhibitors should be added for combined treatment and the insulin dose should be adjusted according to the glycated hemoglobin level."
        }
      ],
      "paragraph_en": "The rapid advice guideline recommends DPP-4 inhibitors combined with basal insulin for glucose-lowering treatment in patients with type 2 diabetes, pointing out that when basal insulin is used for treatment and the glycated hemoglobin level is still poorly controlled, DPP-4 inhibitors should be added for combined treatment and the insulin dose should be adjusted according to the glycated hemoglobin level."
    },
    {
      "paragraph_id": "16",
      "paragraph": "B.肝功能不全：西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整，尚无严重肝功能不全患者使用的临床经验；维格列汀不推荐用于开始给药前血清谷丙转氨酶或谷草转氨酶大于正常上限3倍的患者，罕见有肝功能障碍(包括肝炎)报告，但需要定期检测肝酶，对用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用；沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者；利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量；阿格列汀在肝功能检查结果异常的患者中应慎重使用，如患者报告发生可能提示肝损伤的症状，应迅速进行肝功能检查，出现具有临床意义的肝酶升高或肝功能检查异常结果持续或恶化时，应停用，如未发现引起肝功能检查异常的其他原因，则不要再次使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "B.肝功能不全：西格列汀用于轻度或中度肝功能不全的患者，不需要进行剂量调整，尚无严重肝功能不全患者使用的临床经验；维格列汀不推荐用于开始给药前血清谷丙转氨酶或谷草转氨酶大于正常上限3倍的患者，罕见有肝功能障碍(包括肝炎)报告，但需要定期检测肝酶，对用药中发生肝酶异常者，在肝功能检测恢复正常后，不建议重新使用；沙格列汀用于中度肝功能不全的患者时需谨慎，不推荐用于重度肝功能不全的患者；利格列汀在不同程度肝功能不全的患者中使用，均不需要调整剂量；阿格列汀在肝功能检查结果异常的患者中应慎重使用，如患者报告发生可能提示肝损伤的症状，应迅速进行肝功能检查，出现具有临床意义的肝酶升高或肝功能检查异常结果持续或恶化时，应停用，如未发现引起肝功能检查异常的其他原因，则不要再次使用。",
          "start_idx": 0,
          "end_idx": 336,
          "entities": [
            {
              "entity_id": "T516",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T517",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 19,
              "end_idx": 24,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T518",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 47,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T519",
              "entity": "肝功能障碍",
              "entity_type": "Disease",
              "start_idx": 99,
              "end_idx": 104,
              "entity_en": "Liver dysfunction"
            },
            {
              "entity_id": "T520",
              "entity": "肝炎",
              "entity_type": "Disease",
              "start_idx": 107,
              "end_idx": 109,
              "entity_en": "hepatitis"
            },
            {
              "entity_id": "T521",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 168,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T522",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 183,
              "end_idx": 188,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T523",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 201,
              "end_idx": 206,
              "entity_en": "Hepatic insufficiency"
            },
            {
              "entity_id": "T524",
              "entity": "肝损伤",
              "entity_type": "Disease",
              "start_idx": 257,
              "end_idx": 260,
              "entity_en": "Liver damage"
            },
            {
              "entity_id": "T525",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "liver"
            },
            {
              "entity_id": "T526",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 19,
              "end_idx": 20,
              "entity_en": "liver"
            },
            {
              "entity_id": "T527",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 42,
              "end_idx": 43,
              "entity_en": "liver"
            },
            {
              "entity_id": "T528",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 99,
              "end_idx": 100,
              "entity_en": "liver"
            },
            {
              "entity_id": "T529",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 107,
              "end_idx": 108,
              "entity_en": "liver"
            },
            {
              "entity_id": "T530",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 163,
              "end_idx": 164,
              "entity_en": "liver"
            },
            {
              "entity_id": "T531",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 183,
              "end_idx": 184,
              "entity_en": "liver"
            },
            {
              "entity_id": "T532",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 201,
              "end_idx": 202,
              "entity_en": "liver"
            },
            {
              "entity_id": "T533",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 257,
              "end_idx": 258,
              "entity_en": "liver"
            },
            {
              "entity_id": "T534",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T535",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T536",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 155,
              "end_idx": 159,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T537",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 196,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T538",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 222,
              "end_idx": 226,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T539",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "Mild"
            },
            {
              "entity_id": "T540",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T541",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "serious"
            },
            {
              "entity_id": "T542",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 161,
              "end_idx": 163,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T543",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 181,
              "end_idx": 183,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T544",
              "entity": "血清谷丙转氨酶",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 78,
              "entity_en": "Serum ALT"
            },
            {
              "entity_id": "T545",
              "entity": "谷草转氨酶",
              "entity_type": "Test_items",
              "start_idx": 79,
              "end_idx": 84,
              "entity_en": "Aspartate aminotransferase"
            },
            {
              "entity_id": "T546",
              "entity": "肝酶",
              "entity_type": "Test_items",
              "start_idx": 120,
              "end_idx": 122,
              "entity_en": "Liver enzymes"
            },
            {
              "entity_id": "T547",
              "entity": "肝酶",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 131,
              "entity_en": "Liver enzymes"
            },
            {
              "entity_id": "T548",
              "entity": "肝酶",
              "entity_type": "Test_items",
              "start_idx": 284,
              "end_idx": 286,
              "entity_en": "Liver enzymes"
            },
            {
              "entity_id": "T549",
              "entity": "大于正常上限3倍",
              "entity_type": "Test_Value",
              "start_idx": 84,
              "end_idx": 92,
              "entity_en": "More than 3 times the upper limit of normal"
            },
            {
              "entity_id": "T550",
              "entity": "异常",
              "entity_type": "Test_Value",
              "start_idx": 131,
              "end_idx": 133,
              "entity_en": "abnormal"
            },
            {
              "entity_id": "T551",
              "entity": "肝功能检测",
              "entity_type": "Test",
              "start_idx": 136,
              "end_idx": 141,
              "entity_en": "Liver function tests"
            },
            {
              "entity_id": "T552",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 227,
              "end_idx": 232,
              "entity_en": "Liver function tests"
            },
            {
              "entity_id": "T553",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 269,
              "end_idx": 274,
              "entity_en": "Liver function tests"
            },
            {
              "entity_id": "T554",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 289,
              "end_idx": 294,
              "entity_en": "Liver function tests"
            },
            {
              "entity_id": "T555",
              "entity": "肝功能检查",
              "entity_type": "Test",
              "start_idx": 315,
              "end_idx": 320,
              "entity_en": "Liver function tests"
            },
            {
              "entity_id": "T556",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 286,
              "end_idx": 288,
              "entity_en": "Elevated"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R180",
              "head_entity_id": "T525",
              "tail_entity_id": "T516"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R181",
              "head_entity_id": "T534",
              "tail_entity_id": "T516"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R182",
              "head_entity_id": "T526",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R183",
              "head_entity_id": "T534",
              "tail_entity_id": "T517"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R184",
              "head_entity_id": "T527",
              "tail_entity_id": "T518"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R185",
              "head_entity_id": "T528",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R186",
              "head_entity_id": "T535",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R187",
              "head_entity_id": "T546",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R188",
              "head_entity_id": "T547",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R189",
              "head_entity_id": "T529",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T535",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R191",
              "head_entity_id": "T546",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R192",
              "head_entity_id": "T547",
              "tail_entity_id": "T520"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R193",
              "head_entity_id": "T530",
              "tail_entity_id": "T521"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R194",
              "head_entity_id": "T536",
              "tail_entity_id": "T521"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R195",
              "head_entity_id": "T531",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R196",
              "head_entity_id": "T532",
              "tail_entity_id": "T523"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R197",
              "head_entity_id": "T533",
              "tail_entity_id": "T524"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R198",
              "head_entity_id": "T553",
              "tail_entity_id": "T524"
            }
          ],
          "sentence_en": "B. Hepatic impairment: Sitagliptin is used for patients with mild or moderate hepatic impairment and does not require dose adjustment. There is no clinical experience in patients with severe hepatic impairment. Vildagliptin is not recommended for patients with serum alanine aminotransferase or aspartate aminotransferase greater than 3 times the upper limit of normal before starting medication. There are rare reports of liver dysfunction (including hepatitis), but liver enzymes need to be tested regularly. For patients with abnormal liver enzymes during medication, it is not recommended to reuse it after liver function tests return to normal. Saxagliptin should be used with caution in patients with moderate hepatic impairment and is not recommended for patients with severe hepatic impairment. Linagliptin does not require dose adjustment when used in patients with varying degrees of hepatic impairment. Alogliptin should be used with caution in patients with abnormal liver function test results. If the patient reports symptoms that may indicate liver damage, liver function tests should be performed promptly. If clinically significant liver enzyme elevations occur or abnormal liver function test results persist or worsen, the drug should be discontinued. If no other causes of abnormal liver function tests are found, it should not be used again."
        }
      ],
      "paragraph_en": "B. Hepatic impairment: Sitagliptin is used for patients with mild or moderate hepatic impairment and does not require dose adjustment. There is no clinical experience in patients with severe hepatic impairment. Vildagliptin is not recommended for patients with serum alanine aminotransferase or aspartate aminotransferase greater than 3 times the upper limit of normal before starting medication. There are rare reports of liver dysfunction (including hepatitis), but liver enzymes need to be tested regularly. For patients with abnormal liver enzymes during medication, it is not recommended to reuse it after liver function tests return to normal. Saxagliptin should be used with caution in patients with moderate hepatic impairment and is not recommended for patients with severe hepatic impairment. Linagliptin does not require dose adjustment when used in patients with varying degrees of hepatic impairment. Alogliptin should be used with caution in patients with abnormal liver function test results. If patients report symptoms that may indicate liver damage, liver function tests should be performed promptly. If clinically significant liver enzyme elevations occur or abnormal liver function test results persist or worsen, the drug should be discontinued and should not be used again if no other causes of abnormal liver function tests are found."
    },
    {
      "paragraph_id": "15",
      "paragraph": "A.肾功能不全：西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病患者时需要根据肌酐清除率调整剂量；维格列汀在中度或重度肾功能不全或需要接受血液透析治疗的终末期肾病患者中的应用经验有限，因此不推荐此类患者使用；沙格列汀在轻度肾功能不全的患者中无需调整剂量，中重度肾功能不全的患者应将剂量调整为2.5毫克，每日1次，在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用；利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量；阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受损或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。在开始使用阿格列汀前应评估肾功能并定期复查。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "A.肾功能不全：西格列汀通过肾脏代谢，用于中、重度肾功能不全及需要透析的终末期肾病患者时需要根据肌酐清除率调整剂量；维格列汀在中度或重度肾功能不全或需要接受血液透析治疗的终末期肾病患者中的应用经验有限，因此不推荐此类患者使用；沙格列汀在轻度肾功能不全的患者中无需调整剂量，中重度肾功能不全的患者应将剂量调整为2.5毫克，每日1次，在重度肾功能不全的患者中临床研究经验有限，因此不推荐使用；利格列汀极少经过肾脏排泄，在不同程度肾功能不全的患者中使用，均不需要调整剂量；阿格列汀在中度肾功能受损患者中使用剂量为推荐剂量减半，重度肾功能受损或终末期肾功能衰竭患者中使用剂量为推荐量的四分之一。",
          "start_idx": 0,
          "end_idx": 293,
          "entities": [
            {
              "entity_id": "T557",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T558",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 39,
              "end_idx": 41,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T559",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 88,
              "end_idx": 90,
              "entity_en": "Kidney disease"
            },
            {
              "entity_id": "T560",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 212,
              "end_idx": 217,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T561",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T562",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T563",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 120,
              "end_idx": 125,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T564",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 144,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T565",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 168,
              "end_idx": 173,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T566",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 240,
              "end_idx": 245,
              "entity_en": "Impaired renal function"
            },
            {
              "entity_id": "T567",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 262,
              "end_idx": 267,
              "entity_en": "Impaired renal function"
            },
            {
              "entity_id": "T568",
              "entity": "肾功能衰竭",
              "entity_type": "Disease",
              "start_idx": 271,
              "end_idx": 276,
              "entity_en": "Renal failure"
            },
            {
              "entity_id": "T569",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T570",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T571",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 39,
              "end_idx": 40,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T572",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 68,
              "end_idx": 69,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T573",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 88,
              "end_idx": 89,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T574",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 120,
              "end_idx": 121,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T575",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 139,
              "end_idx": 140,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T576",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 168,
              "end_idx": 169,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T577",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 212,
              "end_idx": 213,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T578",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 240,
              "end_idx": 241,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T579",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 262,
              "end_idx": 263,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T580",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 271,
              "end_idx": 272,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T581",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T582",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T583",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 117,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T584",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 194,
              "end_idx": 198,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T585",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 233,
              "end_idx": 237,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T587",
              "entity": "中、重度",
              "entity_type": "Level",
              "start_idx": 21,
              "end_idx": 25,
              "entity_en": "Moderate to severe"
            },
            {
              "entity_id": "T588",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 63,
              "end_idx": 65,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T589",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 66,
              "end_idx": 68,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T590",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "Mild"
            },
            {
              "entity_id": "T591",
              "entity": "中重度",
              "entity_type": "Level",
              "start_idx": 136,
              "end_idx": 139,
              "entity_en": "Moderate to severe"
            },
            {
              "entity_id": "T592",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 166,
              "end_idx": 168,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T593",
              "entity": "中度",
              "entity_type": "Level",
              "start_idx": 238,
              "end_idx": 240,
              "entity_en": "Moderate"
            },
            {
              "entity_id": "T594",
              "entity": "重度",
              "entity_type": "Level",
              "start_idx": 260,
              "end_idx": 262,
              "entity_en": "Severe"
            },
            {
              "entity_id": "T595",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T596",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 85,
              "end_idx": 88,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T597",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 268,
              "end_idx": 271,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T598",
              "entity": "终末期",
              "entity_type": "Class",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "Terminal stage"
            },
            {
              "entity_id": "T599",
              "entity": "肌酐清除率",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 53,
              "entity_en": "Creatinine clearance"
            },
            {
              "entity_id": "T600",
              "entity": "透析",
              "entity_type": "Treatment",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "Dialysis"
            },
            {
              "entity_id": "T601",
              "entity": "血液透析",
              "entity_type": "Treatment",
              "start_idx": 78,
              "end_idx": 82,
              "entity_en": "Hemodialysis"
            },
            {
              "entity_id": "T602",
              "entity": "2.5毫克",
              "entity_type": "Amount",
              "start_idx": 154,
              "end_idx": 159,
              "entity_en": "2.5 mg"
            },
            {
              "entity_id": "T603",
              "entity": "每日1次",
              "entity_type": "Frequency",
              "start_idx": 160,
              "end_idx": 164,
              "entity_en": "1 time per day"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R199",
              "head_entity_id": "T569",
              "tail_entity_id": "T557"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R200",
              "head_entity_id": "T581",
              "tail_entity_id": "T557"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R201",
              "head_entity_id": "T599",
              "tail_entity_id": "T557"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R202",
              "head_entity_id": "T571",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R203",
              "head_entity_id": "T581",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R204",
              "head_entity_id": "T598",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R205",
              "head_entity_id": "T599",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R206",
              "head_entity_id": "T600",
              "tail_entity_id": "T558"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R207",
              "head_entity_id": "T573",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R208",
              "head_entity_id": "T596",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R209",
              "head_entity_id": "T601",
              "tail_entity_id": "T559"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R210",
              "head_entity_id": "T577",
              "tail_entity_id": "T560"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R211",
              "head_entity_id": "T584",
              "tail_entity_id": "T560"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R212",
              "head_entity_id": "T570",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R213",
              "head_entity_id": "T581",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R214",
              "head_entity_id": "T599",
              "tail_entity_id": "T561"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R215",
              "head_entity_id": "T572",
              "tail_entity_id": "T562"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R216",
              "head_entity_id": "T574",
              "tail_entity_id": "T563"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R217",
              "head_entity_id": "T583",
              "tail_entity_id": "T563"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R218",
              "head_entity_id": "T575",
              "tail_entity_id": "T564"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T583",
              "tail_entity_id": "T564"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R220",
              "head_entity_id": "T576",
              "tail_entity_id": "T565"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R221",
              "head_entity_id": "T578",
              "tail_entity_id": "T566"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R222",
              "head_entity_id": "T585",
              "tail_entity_id": "T566"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R223",
              "head_entity_id": "T579",
              "tail_entity_id": "T567"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R224",
              "head_entity_id": "T585",
              "tail_entity_id": "T567"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R225",
              "head_entity_id": "T580",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R226",
              "head_entity_id": "T585",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R227",
              "head_entity_id": "T597",
              "tail_entity_id": "T568"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R228",
              "head_entity_id": "T602",
              "tail_entity_id": "T583"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R229",
              "head_entity_id": "T603",
              "tail_entity_id": "T583"
            }
          ],
          "sentence_en": "A. Renal Insufficiency: Sitagliptin is metabolized by the kidneys. When used in patients with moderate to severe renal impairment and end-stage renal disease requiring dialysis, the dose needs to be adjusted according to creatinine clearance. There is limited experience in the use of vildagliptin in patients with moderate or severe renal impairment or end-stage renal disease requiring hemodialysis, so it is not recommended for such patients. There is no need to adjust the dose of saxagliptin in patients with mild renal impairment. The dose should be adjusted to 2.5 mg once a day for patients with moderate to severe renal impairment. There is limited clinical research experience in patients with severe renal impairment, so it is not recommended. Linagliptin is rarely excreted by the kidneys and does not require dose adjustment when used in patients with varying degrees of renal impairment. The dose of alogliptin in patients with moderate renal impairment is half of the recommended dose, and the dose in patients with severe renal impairment or end-stage renal failure is one-quarter of the recommended dose."
        },
        {
          "sentence_id": "1",
          "sentence": "在开始使用阿格列汀前应评估肾功能并定期复查。",
          "start_idx": 293,
          "end_idx": 315,
          "entities": [
            {
              "entity_id": "T586",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9,
              "entity_en": "Alogliptin"
            }
          ],
          "relations": [],
          "sentence_en": "Renal function should be assessed before starting alogliptin and reviewed periodically."
        }
      ],
      "paragraph_en": "A. Renal insufficiency: Sitagliptin is metabolized by the kidneys. When used in patients with moderate or severe renal insufficiency and end-stage renal disease requiring dialysis, the dose needs to be adjusted according to the creatinine clearance rate. Vildagliptin has limited experience in the use of patients with moderate or severe renal insufficiency or end-stage renal disease requiring hemodialysis, so it is not recommended for such patients. Saxagliptin does not require dose adjustment in patients with mild renal insufficiency. Patients with moderate to severe renal insufficiency should have their dose adjusted to 2.5 mg once a day. Clinical research experience in patients with severe renal insufficiency is limited, so it is not recommended. Linagliptin is rarely excreted by the kidneys and does not require dose adjustment when used in patients with varying degrees of renal insufficiency. The dose of alogliptin in patients with moderate renal impairment is half of the recommended dose, and the dose in patients with severe renal impairment or end-stage renal failure is one-quarter of the recommended dose. Renal function should be assessed before starting alogliptin and reviewed regularly."
    }
  ]
}